| Year |
Citation |
Score |
| 2024 |
Singh R, Hahn MK, Bansal Y, Agarwal SM, Remington G. Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia. The International Journal of Neuropsychopharmacology. PMID 38195245 DOI: 10.1093/ijnp/pyae005 |
0.602 |
|
| 2023 |
Agarwal SM, Dissanayake J, Agid O, Bowie C, Brierley N, Chintoh A, De Luca V, Diaconescu A, Gerretsen P, Graff-Guerrero A, Hawco C, Herman Y, Hill S, Hum K, Husain MO, ... ... Remington G, et al. Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol. Plos One. 18: e0288354. PMID 37733693 DOI: 10.1371/journal.pone.0288354 |
0.551 |
|
| 2023 |
Smith ECC, Au E, Pereira S, Sharma E, Venkatasubramanian G, Remington G, Agarwal SM, Hahn M. Clinical improvement in schizophrenia during antipsychotic treatment in relation to changes in glucose parameters: A systematic review. Psychiatry Research. 328: 115472. PMID 37722239 DOI: 10.1016/j.psychres.2023.115472 |
0.602 |
|
| 2023 |
Wu S, Stogios N, Hahn M, Navagnanavel J, Emami Z, Chintoh A, Gerretsen P, Graff-Guerrero A, Rajji TK, Remington G, Agarwal SM. Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis. Plos One. 18: e0286887. PMID 37379265 DOI: 10.1371/journal.pone.0286887 |
0.493 |
|
| 2023 |
Prasad F, Hahn MK, Chintoh AF, Remington G, Foussias G, Rotenberg M, Agarwal SM. Depression in caregivers of patients with schizophrenia: a scoping review. Social Psychiatry and Psychiatric Epidemiology. PMID 37308691 DOI: 10.1007/s00127-023-02504-1 |
0.579 |
|
| 2023 |
Lee J, Costa-Dookhan K, Panganiban K, MacKenzie N, Treen QC, Chintoh A, Remington G, Müller DJ, Sockalingam S, Gerretsen P, Sanches M, Karnovsky A, Stringer KA, Ellingrod VL, Tso IF, et al. Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study. Frontiers in Psychiatry. 14: 1169787. PMID 37168086 DOI: 10.3389/fpsyt.2023.1169787 |
0.529 |
|
| 2023 |
Kim J, Song J, Kambari Y, Plitman E, Shah P, Iwata Y, Caravaggio F, Brown EE, Nakajima S, Chakravarty MM, De Luca V, Remington G, Graff-Guerrero A, Gerretsen P. Cortical thinning in relation to impaired insight into illness in patients with treatment resistant schizophrenia. Schizophrenia (Heidelberg, Germany). 9: 27. PMID 37120642 DOI: 10.1038/s41537-023-00347-y |
0.332 |
|
| 2023 |
Prasad F, De R, Korann V, Chintoh AF, Remington G, Ebdrup BH, Siskind D, Knop FK, Vilsbøll T, Fink-Jensen A, Hahn MK, Agarwal SM. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series. Therapeutic Advances in Psychopharmacology. 13: 20451253231165169. PMID 37113745 DOI: 10.1177/20451253231165169 |
0.518 |
|
| 2022 |
Stogios N, Hamel L, Smith E, Sanches M, Remington G, Voineskos A, Dash S, Graff-Guerrero A, Hahn M, Agarwal SM. Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls. Plos One. 17: e0277211. PMID 36441736 DOI: 10.1371/journal.pone.0277211 |
0.533 |
|
| 2022 |
Kim J, Romero L, Iwata Y, Caravaggio F, Remington G, Graff-Guerrero A, Gerretsen P, Agid O. Impaired insight into illness is unrelated to subjective happiness, success, and life satisfaction in schizophrenia. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 34: 233-239. PMID 36282606 DOI: 10.12788/acp.0081 |
0.326 |
|
| 2022 |
Castellani LN, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S, Hamel L, Alganem K, Ryan WG, Zhang X, Au E, Chintoh A, Remington G, Agarwal SM, Giacca A, et al. Antipsychotics impair regulation of glucose metabolism by central glucose. Molecular Psychiatry. PMID 36241692 DOI: 10.1038/s41380-022-01798-y |
0.539 |
|
| 2022 |
Agarwal SM, Stogios N, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia. The Cochrane Database of Systematic Reviews. 10: CD013337. PMID 36190739 DOI: 10.1002/14651858.CD013337.pub2 |
0.583 |
|
| 2022 |
Takeuchi H, Sanches M, Borlido C, Remington G. Consistency of adherence to antipsychotics between two bottles in patients with schizophrenia. Schizophrenia Research. 248: 194-195. PMID 36087495 DOI: 10.1016/j.schres.2022.08.013 |
0.357 |
|
| 2022 |
Smith E, Stogios N, Au E, Maksyutynska K, De R, Ji A, Sørensen ME, John LS, Lin HY, Desarkar P, Lunsky Y, Remington G, Hahn M, Agarwal SM. The Metabolic Adverse Effects of Antipsychotic Use in Individuals with Intellectual and/or Developmental Disability (IDD): A Systematic Review and Meta-Analysis. Acta Psychiatrica Scandinavica. PMID 35894550 DOI: 10.1111/acps.13484 |
0.524 |
|
| 2022 |
Stogios N, Maksyutynska K, Navagnanavel J, Sanches M, Powell V, Gerretsen P, Graff-Guerrero A, Chintoh AF, Foussias G, Remington G, Hahn MK, Agarwal SM. Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica. PMID 35726126 DOI: 10.1111/acps.13462 |
0.585 |
|
| 2022 |
Singh R, Stogios N, Smith E, Lee J, Maksyutynsk K, Au E, Wright DC, De Palma G, Graff-Guerrero A, Gerretsen P, Müller DJ, Remington G, Hahn M, Agarwal SM. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Therapeutic Advances in Psychopharmacology. 12: 20451253221096525. PMID 35600753 DOI: 10.1177/20451253221096525 |
0.573 |
|
| 2022 |
Wada M, Noda Y, Iwata Y, Tsugawa S, Yoshida K, Tani H, Hirano Y, Koike S, Sasabayashi D, Katayama H, Plitman E, Ohi K, Ueno F, Caravaggio F, Koizumi T, ... ... Remington G, et al. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Molecular Psychiatry. PMID 35444257 DOI: 10.1038/s41380-022-01572-0 |
0.321 |
|
| 2022 |
Bidzinski KK, Lowe DJE, Sanches M, Sorkhou M, Boileau I, Kiang M, Blumberger DM, Remington G, Ma C, Castle DJ, Rabin RA, George TP. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. Npj Schizophrenia. 8: 2. PMID 35210458 DOI: 10.1038/s41537-022-00210-6 |
0.308 |
|
| 2022 |
Gerritsen CJ, Goldberg JO, Kiang M, Remington G, Foussias G, Eastwood JD. Distinct profiles of psychological and neuropsychological functions underlying goal-directed pursuit in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 48674221077031. PMID 35191327 DOI: 10.1177/00048674221077031 |
0.323 |
|
| 2022 |
Krzyzanowski DJ, Wu S, Carnovale M, Agarwal SM, Remington G, Goghari V. Trait Anhedonia in Schizophrenia: A Systematic Review and Comparative Meta-analysis. Schizophrenia Bulletin. 48: 335-346. PMID 34891171 DOI: 10.1093/schbul/sbab136 |
0.303 |
|
| 2021 |
Agid O, Remington G, Fung C, Nightingale NM, Duclos M, Anger GJ. Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study : Modèles concrets d'utilisation d'antipsychotiques injectables à action prolongée au Canada : une étude rétrospective. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 7067437211055413. PMID 34792401 DOI: 10.1177/07067437211055413 |
0.326 |
|
| 2021 |
Itahashi T, Noda Y, Iwata Y, Tarumi R, Tsugawa S, Plitman E, Honda S, Caravaggio F, Kim J, Matsushita K, Gerretsen P, Uchida H, Remington G, Mimura M, Aoki YY, et al. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neuroimage. Clinical. 32: 102852. PMID 34638035 DOI: 10.1016/j.nicl.2021.102852 |
0.347 |
|
| 2021 |
Takeuchi H, Sanches M, Borlido C, Agid O, Remington G. Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications. Schizophrenia Research. 237: 202-207. PMID 34563881 DOI: 10.1016/j.schres.2021.08.017 |
0.329 |
|
| 2021 |
Smith E, Singh R, Lee J, Colucci L, Graff-Guerrero A, Remington G, Hahn M, Agarwal SM. Adiposity in Schizophrenia: A Systematic Review and Meta-Analysis. Acta Psychiatrica Scandinavica. PMID 34458979 DOI: 10.1111/acps.13365 |
0.613 |
|
| 2021 |
Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34446830 DOI: 10.1038/s41386-021-01163-7 |
0.54 |
|
| 2021 |
Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: Antipsychotics and Drug Development. Behavioural Brain Research. 113507. PMID 34352293 DOI: 10.1016/j.bbr.2021.113507 |
0.609 |
|
| 2021 |
Krzyzanowski D, Agid O, Goghari V, Remington G. Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. Schizophrenia Research. Cognition. 26: 100205. PMID 34258238 DOI: 10.1016/j.scog.2021.100205 |
0.32 |
|
| 2021 |
Krzyzanowski D, Agid O, Goghari V, Remington G. Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. Schizophrenia Research. Cognition. 26: 100205. PMID 34258238 DOI: 10.1016/j.scog.2021.100205 |
0.32 |
|
| 2021 |
Stogios N, Gdanski A, Gerretsen P, Chintoh AF, Graff-Guerrero A, Rajji TK, Remington G, Hahn MK, Agarwal SM. Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health. Npj Schizophrenia. 7: 22. PMID 33903594 DOI: 10.1038/s41537-021-00151-6 |
0.596 |
|
| 2021 |
Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani A, Matheson K, Chintoh AF, Kramer CK, Voineskos AN, Graff-Guerrero A, Remington GJ, et al. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Translational Psychiatry. 11: 219. PMID 33854039 DOI: 10.1038/s41398-021-01338-2 |
0.584 |
|
| 2021 |
Kanagasundaram P, Lee J, Prasad F, Costa-Dookhan KA, Hamel L, Gordon M, Remington G, Hahn MK, Agarwal SM. Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis. Frontiers in Psychiatry. 12: 642403. PMID 33815174 DOI: 10.3389/fpsyt.2021.642403 |
0.553 |
|
| 2021 |
Costa-Dookhan KA, Rajji TK, Tran VN, Bowden S, Mueller DJ, Remington GJ, Agarwal SM, Hahn MK. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia. Scientific Reports. 11: 2004. PMID 33479273 DOI: 10.1038/s41598-021-81493-0 |
0.582 |
|
| 2020 |
Grimes KM, Foussias G, Remington G, Kalahani-Bargis K, Zakzanis KK. Stability of Verbal Fluency in Outpatients with Schizophrenia. Psychiatry Research. 113528. PMID 33189369 DOI: 10.1016/j.psychres.2020.113528 |
0.339 |
|
| 2020 |
Daniell K, Kim J, Iwata Y, Caravaggio F, Brown E, Remington G, Agid O, Graff-Guerrero A, Gerretsen P. Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia. Journal of Psychiatric Research. PMID 33168197 DOI: 10.1016/j.jpsychires.2020.10.016 |
0.35 |
|
| 2020 |
Takeuchi H, Borlido C, Sanches M, Teo C, Harber L, Agid O, Remington G. Adherence to Clozapine vs. Other Antipsychotics in Schizophrenia. Acta Psychiatrica Scandinavica. PMID 32627168 DOI: 10.1111/Acps.13208 |
0.389 |
|
| 2020 |
Remington G, Powell V. Clozapine and COVID-19. Journal of Psychiatry & Neuroscience : Jpn. 45: E1. PMID 32584527 DOI: 10.1503/Jpn.2045301 |
0.435 |
|
| 2020 |
Remington G, Kapur S. Antipsychotics Circa 2020: What Are We Thinking? Neuropharmacology. 108181. PMID 32533978 DOI: 10.1016/j.neuropharm.2020.108181 |
0.347 |
|
| 2020 |
Takeuchi H, Remington G. Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Journal of Psychopharmacology (Oxford, England). 269881120922964. PMID 32448023 DOI: 10.1177/0269881120922964 |
0.418 |
|
| 2020 |
Takeuchi H, MacKenzie NE, Samaroo D, Agid O, Remington G, Leucht S. Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. Schizophrenia Bulletin. PMID 32415847 DOI: 10.1093/Schbul/Sbaa063 |
0.452 |
|
| 2020 |
Maes MS, Lu JY, Tiwari AK, Freeman N, de Luca V, Müller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL, Zai CC. Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. Drug Development Research. PMID 32394511 DOI: 10.1002/Ddr.21681 |
0.449 |
|
| 2020 |
Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to Oral Antipsychotics Measured by Electronic Adherence Monitoring in Schizophrenia: A Systematic Review and Meta-analysis. Cns Drugs. PMID 32219681 DOI: 10.1007/S40263-020-00713-9 |
0.407 |
|
| 2020 |
Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of Psychiatric Research. 124: 151-158. PMID 32169688 DOI: 10.1016/J.Jpsychires.2020.02.032 |
0.637 |
|
| 2020 |
Zipursky RB, Odejayi G, Agid O, Remington G. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication. Schizophrenia Research. PMID 32115315 DOI: 10.1016/J.Schres.2020.02.009 |
0.419 |
|
| 2020 |
Lee J, Yee JY, See YM, Tang C, Ng BT, Chowbay B, Remington G. M215. Factors Associated With Clozapine Response And Resistance In Schizophrenia Schizophrenia Bulletin. 46. DOI: 10.1093/Schbul/Sbaa030.527 |
0.395 |
|
| 2020 |
Stogios N, Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.915 |
0.625 |
|
| 2020 |
Kim J, Iwata Y, Plitman E, Caravaggio F, Shah P, Luca VD, Remington G, Graff-Guerrero A, Gerretsen P. Improving Insight in Non-Treatment-Resistant Patients With Schizophrenia With Transcranial Direct Current Stimulation Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.488 |
0.407 |
|
| 2020 |
Islam F, Maciukiewicz M, Freeman N, Huang E, Tiwari AK, Mulsant BH, Pollock BG, Remington G, Kennedy JL, Rajji TK, Mueller DJ. Contributions of Cholinergic Receptor Muscarinic 1 (CHRM1) and CYP1A2 Gene Variants on the Effects of Plasma Ratio of Clozapine/N-Desmethylclozapine on Working Memory in Schizophrenia Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.415 |
0.367 |
|
| 2020 |
Hahn M, Agarwal SM, Costa-Dookhan K, Roshni P, Nicole M, Cauccio-Treen Q, Caravaggio F, Hashim E, Kirpalani A, Chintoh A, Kramer C, Voineskos A, Graff-Guerrero A, Remington G. Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: A Double-Blind Randomized Pilot Study Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1057 |
0.615 |
|
| 2020 |
Costa-Dookhan K, Agarwal SM, Chintoh A, MacKenzie N, Leavitt D, Treen QC, Remington G, Ward K, Hahn M. Investigating Metabolic Dysfunction and Metabolomic Profile Changes in Antipsychotic Naive Patients Biological Psychiatry. 87. DOI: 10.1016/J.Biopsych.2020.02.1041 |
0.574 |
|
| 2019 |
Zai CC, Tiwari AK, Zai GC, Freeman N, Pouget JG, Greco J, Tampakeras M, Shaikh SA, Herbert D, Emmerson H, Cheema SY, Braganza N, Müller DJ, Voineskos AN, Remington G, et al. Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. Frontiers in Pharmacology. 10: 1339. PMID 31849639 DOI: 10.3389/Fphar.2019.01339 |
0.426 |
|
| 2019 |
Kim J, Plitman E, Iwata Y, Nakajima S, Mar W, Patel R, Chavez S, Chung JK, Caravaggio F, Chakravarty MM, Remington G, Gerretsen P, Graff-Guerrero A. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109839. PMID 31843627 DOI: 10.1016/J.Pnpbp.2019.109839 |
0.426 |
|
| 2019 |
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M, Fujii S, Miyazaki T, Chakravarty MM, Uchida H, Remington G, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31842203 DOI: 10.1038/S41386-019-0589-Z |
0.403 |
|
| 2019 |
Puveendrakumaran P, Fervaha G, Caravaggio F, Remington G. Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia. Psychiatry Research. 112683. PMID 31818543 DOI: 10.1016/J.Psychres.2019.112683 |
0.422 |
|
| 2019 |
Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. The clozapine to norclozapine ratio: A narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opinion On Drug Safety. PMID 31770500 DOI: 10.1080/14740338.2020.1698545 |
0.587 |
|
| 2019 |
Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European Archives of Psychiatry and Clinical Neuroscience. PMID 31428862 DOI: 10.1007/S00406-019-01053-6 |
0.633 |
|
| 2019 |
Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. Journal of Psychopharmacology (Oxford, England). 269881119862535. PMID 31347436 DOI: 10.1177/0269881119862535 |
0.423 |
|
| 2019 |
Kim J, Plitman E, Nakajima S, Alshehri Y, Iwata Y, Chung JK, Caravaggio F, Menon M, Blumberger DM, Pollock BG, Remington G, De Luca V, Graff-Guerrero A, Gerretsen P. Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia. European Psychiatry : the Journal of the Association of European Psychiatrists. 61: 63-71. PMID 31326732 DOI: 10.1016/J.Eurpsy.2019.06.007 |
0.379 |
|
| 2019 |
Alkelai A, Greenbaum L, Heinzen EL, Baugh EH, Teitelbaum A, Zhu X, Strous RD, Tatarskyy P, Zai CC, Tiwari AK, Tampakeras M, Freeman N, Müller DJ, Voineskos AN, Lieberman JA, ... ... Remington G, et al. New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 109659. PMID 31153890 DOI: 10.1016/J.Pnpbp.2019.109659 |
0.358 |
|
| 2019 |
Berkhout SG, Zaheer J, Remington G. Identity, Subjectivity, and Disorders of Self in Psychosis. Culture, Medicine and Psychiatry. PMID 30980233 DOI: 10.1007/S11013-019-09631-Y |
0.334 |
|
| 2019 |
Caravaggio F, Iwata Y, Kim J, Shah P, Gerretsen P, Remington G, Graff-Guerrero A. What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy. Neuropharmacology. PMID 30940535 DOI: 10.1016/J.Neuropharm.2019.03.034 |
0.348 |
|
| 2019 |
Song J, Borlido C, De Luca V, Burton L, Remington G. Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry Research. 274: 409-413. PMID 30852435 DOI: 10.1016/J.Psychres.2019.02.050 |
0.38 |
|
| 2019 |
Shah P, Iwata Y, Caravaggio F, Plitman E, Brown EE, Kim J, Chan N, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research. PMID 30685395 DOI: 10.1016/j.schres.2019.01.005 |
0.573 |
|
| 2019 |
Shah P, Iwata Y, Brown E, Caravaggio F, Kim J, Sanches M, Takeuchi H, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. S185. Treatment Response Trajectories in Treatment-Resistant Schizophrenia: A Chart Review Study Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.936 |
0.632 |
|
| 2019 |
Carmona ET, Iwata Y, Nakajima S, Plitman E, Caravaggio F, Brown E, Kim J, Shah P, Mar W, Chavez S, Remington G, Gerretsen P, Graff-Guerrero A. S167. Increased N-Acetylaspartate and Myo-Inositol Levels in Clozapine-Responders and Clozapine-Resistant Patients With Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.918 |
0.422 |
|
| 2019 |
Kim J, Iwata Y, Plitman E, Caravaggio F, Shah P, Luca VD, Remington G, Graff-Guerrero A, Gerretsen P. F182. Improving Insight into Psychosis With Transcranial Direct Current Stimulation in Schizophrenia Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.719 |
0.39 |
|
| 2019 |
Kowalchuk C, Castellani L, Teo C, Kanagasundaram P, McIntyre WB, Remington G, Giacca A, Hahn M. 52. Antipsychotics Perturb Glucose Homeostasis by Inhibiting Hypothalamic KATP Channel Activation Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.066 |
0.542 |
|
| 2019 |
Agarwal SM, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, Cohn T, Taylor VH, Remington G, Faulkner GEJ, Hahn M. Pharmacological interventions for prevention of weight gain in people with schizophrenia Cochrane Database of Systematic Reviews. 2019. DOI: 10.1002/14651858.Cd013337 |
0.626 |
|
| 2018 |
Kim J, Iwata Y, Plitman E, Caravaggio F, Chung JK, Shah P, Blumberger DM, Pollock BG, Remington G, Graff-Guerrero A, Gerretsen P. A meta-analysis of transcranial direct current stimulation for schizophrenia: "Is more better?" Journal of Psychiatric Research. 110: 117-126. PMID 30639917 DOI: 10.1016/J.Jpsychires.2018.12.009 |
0.357 |
|
| 2018 |
MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Frontiers in Psychiatry. 9: 622. PMID 30568606 DOI: 10.3389/Fpsyt.2018.00622 |
0.601 |
|
| 2018 |
Duncan MJ, Arbour-Nicitopoulos K, Subramaniapillai M, Remington G, Faulkner G. Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing sitting time among individuals with schizophrenia. Psychiatry Research. 271: 311-318. PMID 30529312 DOI: 10.1016/J.Psychres.2018.11.063 |
0.358 |
|
| 2018 |
Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30514883 DOI: 10.1038/S41386-018-0278-3 |
0.472 |
|
| 2018 |
Siddiqui I, Saperia S, Fervaha G, Da Silva S, Jeffay E, Zakzanis KK, Agid O, Remington G, Foussias G. Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. Schizophrenia Research. PMID 30471980 DOI: 10.1016/J.Schres.2018.10.012 |
0.431 |
|
| 2018 |
Saperia S, Da Silva S, Siddiqui I, Agid O, Daskalakis ZJ, Ravindran A, Voineskos AN, Zakzanis KK, Remington G, Foussias G. Reward-driven decision-making impairments in schizophrenia. Schizophrenia Research. PMID 30442476 DOI: 10.1016/J.Schres.2018.11.004 |
0.402 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Caravaggio F, Kim J, Shah P, Mar W, Chavez S, De Luca V, Mimura M, Remington G, Gerretsen P, Graff-Guerrero A. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry. PMID 30389132 DOI: 10.1016/j.biopsych.2018.09.009 |
0.326 |
|
| 2018 |
Zai CC, Lee FH, Tiwari AK, Lu JY, de Luca V, Maes MS, Herbert D, Shahmirian A, Cheema SY, Zai GC, Atukuri A, Sherman M, Shaikh SA, Tampakeras M, Freeman N, ... ... Remington G, et al. Investigation of the Gene in Tardive Dyskinesia - New Data and Meta-Analysis. Frontiers in Pharmacology. 9: 974. PMID 30283332 DOI: 10.3389/Fphar.2018.00974 |
0.336 |
|
| 2018 |
Castellani LN, Wilkin J, Abela A, Benarroch L, Ahasan Z, Teo C, Wilson V, Kowalchuk C, Giacca A, Remington GJ, Hahn MK. Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding. Psychoneuroendocrinology. 98: 127-130. PMID 30142549 DOI: 10.1016/J.Psyneuen.2018.07.028 |
0.507 |
|
| 2018 |
Lu JY, Tiwari AK, Zai GC, Rastogi A, Shaikh SA, Mueller DJ, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Wong AHC, Kennedy JL, Zai CC. Association study of Disrupted-In-Schizophrenia-1 Gene variants and Tardive Dyskinesia. Neuroscience Letters. PMID 30118782 DOI: 10.1016/J.Neulet.2018.08.007 |
0.427 |
|
| 2018 |
Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, Nakajima S, Hahn M, Remington G, Gerretsen P, Graff-Guerrero A. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review. Psychiatry Research. 268: 114-122. PMID 30015109 DOI: 10.1016/j.psychres.2018.06.070 |
0.599 |
|
| 2018 |
Siddiqui I, Remington G, Fervaha G, Fletcher PJ, Voineskos AN, Saperia S, Zakzanis KK, Foussias G. Objective investigation of activity preference in schizophrenia: A pilot study. Psychiatry Research. 267: 551-559. PMID 29980136 DOI: 10.1016/J.Psychres.2018.05.039 |
0.409 |
|
| 2018 |
Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M. Antipsychotics and glucose metabolism: how brain and body collide. American Journal of Physiology. Endocrinology and Metabolism. PMID 29969315 DOI: 10.1152/Ajpendo.00164.2018 |
0.636 |
|
| 2018 |
Caravaggio F, Scifo E, Sibille EL, Hernandez-Da Mota SE, Gerretsen P, Remington G, Graff-Guerrero A. Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Experimental Eye Research. PMID 29883636 DOI: 10.1016/J.Exer.2018.06.006 |
0.357 |
|
| 2018 |
Da Silva S, Apatsidou A, Saperia S, Siddiqui I, Jeffay E, Voineskos AN, Daskalakis ZJ, Remington G, Zakzanis KK, Foussias G. An Examination of the Multi-Faceted Motivation System in Healthy Young Adults. Frontiers in Psychiatry. 9: 191. PMID 29867611 DOI: 10.3389/Fpsyt.2018.00191 |
0.313 |
|
| 2018 |
Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, Prce I, Wilson AA, Rusjan PM, Sailasuta N, Mizrahi R. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29748630 DOI: 10.1038/S41386-018-0061-5 |
0.317 |
|
| 2018 |
Zipursky RB, Agid O, Remington G. Improving outcomes in schizophrenia by preventing early relapses. The Lancet. Psychiatry. 5: 384-386. PMID 29699735 DOI: 10.1016/S2215-0366(18)30124-X |
0.423 |
|
| 2018 |
Remington G. Book Review: The Schizophrenia Spectrum The Schizophrenia Spectrum . Spaulding W. D. Silverstein S. M. Menditto A. A. , ISBN: 978-0-88937-504-8 . Pages: 94 . Format: softcover. Price: Can $34.80 . Pub Year: 2017 . Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 63: 257. PMID 29630855 DOI: 10.1177/0706743718758042 |
0.326 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis ofH-MRS studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 29580804 DOI: 10.1016/J.Pnpbp.2018.03.016 |
0.329 |
|
| 2018 |
Takeuchi H, Fathi A, Thiyanavadivel S, Agid O, Remington G. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials. The Journal of Clinical Psychiatry. 79. PMID 29570965 DOI: 10.4088/Jcp.17R11489 |
0.431 |
|
| 2018 |
Plitman E, Chavez S, Nakajima S, Iwata Y, Chung JK, Caravaggio F, Kim J, Alshehri Y, Chakravarty MM, De Luca V, Remington G, Gerretsen P, Graff-Guerrero A. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study. Psychiatry Research. 273: 16-24. PMID 29414127 DOI: 10.1016/J.Pscychresns.2018.01.004 |
0.411 |
|
| 2018 |
Fervaha G, Agid O, Foussias G, Takeuchi H, Zakzanis K, Graff-Guerrero A, Remington G. S76. A BEHAVIOURAL ECONOMIC ANALYSIS OF EFFORT-RELATED CHOICE IN SCHIZOPHRENIA Schizophrenia Bulletin. 44: S354-S354. DOI: 10.1093/schbul/sby018.863 |
0.308 |
|
| 2018 |
Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. S225. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OR PREVENTION OF WEIGHT GAIN IN SCHIZOPHRENIA Schizophrenia Bulletin. 44: S413-S413. DOI: 10.1093/schbul/sby018.1012 |
0.578 |
|
| 2018 |
Foussias G, Rao N, Fervaha G, Borlido C, Haber L, Takeuchi H, Mizrahi R, Remington G. F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Schizophrenia Bulletin. 44: S309-S309. DOI: 10.1093/schbul/sby017.756 |
0.317 |
|
| 2018 |
Castellani L, Wilkin J, Ahsan Z, Teo C, Kowalchuk C, Giacca A, Remington G, Hahn M. O10.6. OLANZAPINE IMPAIRS CENTRAL INSULIN ACTION: EFFECTS ON BODY FUEL PREFERENCE IN RATS Schizophrenia Bulletin. 44: S104-S105. DOI: 10.1093/Schbul/Sby015.258 |
0.541 |
|
| 2018 |
Meyer J, Remington G, Norbash A, Burke J, Siegert S, Liang GS. 141 The Effects of Valbenazine on Tardive Dyskinesia: Subgroup Analyses of 3 Randomized, Double-Blind, Placebo-Controlled Trials Cns Spectrums. 23: 88-88. DOI: 10.1017/S1092852918000366 |
0.336 |
|
| 2018 |
Remington G, Thai-Cuarto D, Burke J, Siegert S, Liang GS. 132 Effects of Valbenazine on Depression and Suicidality in Adults With Tardive Dyskinesia: Pooled Results of 3 Double-Blind, Placebo-Controlled Trials Cns Spectrums. 23: 82-83. DOI: 10.1017/S1092852918000287 |
0.334 |
|
| 2018 |
Chintoh A, MacKenzie N, Agarwal SM, Remington G, Hahn M. 2.21 Improvement and Stability of Quality of Life and Clinical Presentation in Youth Who Are First-Episode, Antipsychotic Naïve, and Experience Adverse Metabolic Side Effects Journal of the American Academy of Child & Adolescent Psychiatry. 57: S165. DOI: 10.1016/J.Jaac.2018.09.109 |
0.551 |
|
| 2018 |
Silva SD, Saperia S, Siddiqui I, Agid O, Voineskos A, Daskalakis J, Ravindran A, Zakzanis K, Remington G, Foussias G. F255. Motivation System Impairment Profiles in Schizophrenia and Major Depressive Disorder Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.869 |
0.37 |
|
| 2018 |
Iwata Y, Nakajima S, Plitman E, Chung JK, Caravaggio F, Kim J, Brown E, Shah P, Chan N, Gerretsen P, Mimura M, Chavez S, Remington G, Graff-Guerrero A. F230. Glutamatergic Neurometabolite Levels in Patients With Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton MRS Study Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.844 |
0.354 |
|
| 2018 |
Kowalchuk C, Kanagasundaram P, Remington G, Belsham D, Hahn M. T256. Differential Effects of Antipsychotics on Neuroinflammation and Energy Sensing in a Hypothalamic Cell Line Biological Psychiatry. 83: S228-S229. DOI: 10.1016/J.Biopsych.2018.02.593 |
0.53 |
|
| 2018 |
Castellani L, Wilkin J, Ahsan Z, Kowalchuk C, Teo C, Giacca A, Wright D, Remington G, Hahn M. 259. Olanzapine Impairs Central Insulin Action: Effects on Body Fuel Preference Biological Psychiatry. 83: S105. DOI: 10.1016/J.Biopsych.2018.02.278 |
0.542 |
|
| 2018 |
Agarwal SM, Ahsan Z, Lockwood J, Duncan M, Takeuchi H, Cohn T, Taylor V, Remington G, Faulkner G, Hahn M. S245. A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction or Prevention of Weight Gain in Schizophrenia Biological Psychiatry. 83: S443. DOI: 10.1016/J.Biopsych.2018.02.1137 |
0.62 |
|
| 2018 |
Saperia S, Silva SD, Siddiqui I, Agid O, Daskalakis J, Ravindran A, Voineskos A, Zakzanis K, Remington G, Foussias G. S187. Hedonic Deficits in Schizophrenia and Major Depressive Disorder Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.1079 |
0.385 |
|
| 2017 |
Caravaggio F, Iwata Y, Plitman E, Chavez S, Borlido C, Chung JK, Kim J, Agarwal SM, Gerretsen P, Remington G, Hahn M, Graff-Guerrero A. Reduced insulin sensitivity may be related to less striatal glutamate: An 1H-MRS study in healthy non-obese humans. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29269206 DOI: 10.1016/J.Euroneuro.2017.12.002 |
0.555 |
|
| 2017 |
Saperia S, Da Silva S, Siddiqui I, McDonald K, Agid O, Remington G, Foussias G. Investigating the predictors of happiness, life satisfaction and success in schizophrenia. Comprehensive Psychiatry. 81: 42-47. PMID 29245017 DOI: 10.1016/J.Comppsych.2017.11.005 |
0.448 |
|
| 2017 |
Caravaggio F, Fervaha G, Iwata Y, Plitman E, Chung JK, Nakajima S, Mar W, Gerretsen P, Kim J, Chakravarty MM, Mulsant B, Pollock B, Mamo D, Remington G, Graff-Guerrero A. Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia. International Journal of Geriatric Psychiatry. PMID 29110353 DOI: 10.1002/Gps.4818 |
0.457 |
|
| 2017 |
Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 424-431. PMID 29083297 DOI: 10.1503/jpn.170092 |
0.572 |
|
| 2017 |
Caravaggio F, Fervaha G, Menon M, Remington G, Graff-Guerrero A, Gerretsen P. The neural correlates of apathy in schizophrenia: an exploratory investigation. Neuropsychologia. PMID 29079398 DOI: 10.1016/J.Neuropsychologia.2017.10.027 |
0.455 |
|
| 2017 |
Kowalchuk C, Teo C, Wilson V, Chintoh A, Lam L, Agarwal SM, Giacca A, Remington GJ, Hahn MK. In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact. Journal of Psychiatry & Neuroscience : Jpn. 42: 170092. PMID 29035174 DOI: 10.1503/Jpn.170092 |
0.572 |
|
| 2017 |
Siddiqui I, Remington G, Fletcher PJ, Voineskos AN, Fong JW, Saperia S, Fervaha G, Da Silva S, Zakzanis KK, Foussias G. Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. Schizophrenia Research. PMID 28954705 DOI: 10.1016/J.Schres.2017.09.011 |
0.418 |
|
| 2017 |
Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research. PMID 28844639 DOI: 10.1016/J.Schres.2017.08.012 |
0.47 |
|
| 2017 |
Di Ciano P, Cormick PM, Stefan C, Wong E, Kim A, Remington G, Le Foll B. The effects of buspirone on occupancy of dopamine receptors and the rat gambling task. Psychopharmacology. PMID 28825117 DOI: 10.1007/S00213-017-4715-5 |
0.313 |
|
| 2017 |
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 706743717720448. PMID 28703015 DOI: 10.1177/0706743717720448 |
0.41 |
|
| 2017 |
Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. The British Journal of Psychiatry : the Journal of Mental Science. PMID 28522434 DOI: 10.1192/Bjp.Bp.116.186007 |
0.455 |
|
| 2017 |
Rabin RA, Kozak K, Zakzanis KK, Remington G, Stefan C, Budney AJ, George TP. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophrenia Research. PMID 28506704 DOI: 10.1016/J.Schres.2017.05.006 |
0.429 |
|
| 2017 |
Da Silva S, Saperia S, Siddiqui I, Fervaha G, Agid O, Daskalakis ZJ, Ravindran A, Voineskos AN, Zakzanis KK, Remington G, Foussias G. Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. Psychiatry Research. 254: 112-117. PMID 28460280 DOI: 10.1016/J.Psychres.2017.04.040 |
0.46 |
|
| 2017 |
Koga A, Bani-Fatemi A, Hettige N, Borlido C, Zai C, Strauss J, Gerretsen P, Graff A, Remington G, De Luca V. GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood trauma. Pharmacogenomics. PMID 28453389 DOI: 10.2217/Pgs-2016-0137 |
0.393 |
|
| 2017 |
Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28443616 DOI: 10.1038/Npp.2017.85 |
0.449 |
|
| 2017 |
Caravaggio F, Gerretsen P, Mar W, Chung JK, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A, Menon M. Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning. Psychoneuroendocrinology. 81: 80-87. PMID 28431278 DOI: 10.1016/J.Psyneuen.2017.03.020 |
0.421 |
|
| 2017 |
Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophrenia Research. PMID 28285022 DOI: 10.1016/J.Schres.2017.03.010 |
0.348 |
|
| 2017 |
Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. Schizophrenia Research. PMID 28242107 DOI: 10.1016/j.schres.2017.02.011 |
0.316 |
|
| 2017 |
Takeuchi H, Lee J, Fervaha G, Foussias G, Agid O, Remington G. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial. The Journal of Clinical Psychiatry. 78: 223-228. PMID 28234436 DOI: 10.4088/Jcp.15M10286 |
0.429 |
|
| 2017 |
Fervaha G, Takeuchi H, Foussias G, Hahn MK, Agid O, Remington G. Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome. Early Intervention in Psychiatry. PMID 28230315 DOI: 10.1111/Eip.12405 |
0.666 |
|
| 2017 |
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. PMID 28187219 DOI: 10.1093/Schbul/Sbw221 |
0.44 |
|
| 2017 |
Takeuchi H, Thiyanavadivel S, Fervaha G, Remington G. Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review. Journal of Clinical Psychopharmacology. PMID 28129314 DOI: 10.1097/Jcp.0000000000000662 |
0.32 |
|
| 2017 |
Lanning R, Lett TA, Tiwari AK, Brandl EJ, de Luca V, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Müller DJ, Remington G, Kennedy JL, Zai CC. Association study between the neurexin-1 gene and tardive dyskinesia. Human Psychopharmacology. 32. PMID 28120489 DOI: 10.1002/Hup.2568 |
0.351 |
|
| 2017 |
Egerton A, Howes OD, Houle S, McKenzie K, Valmaggia LR, Bagby MR, Tseng HH, Bloomfield MA, Kenk M, Bhattacharyya S, Suridjan I, Chaddock CA, Winton-Brown TT, Allen P, Rusjan P, ... Remington G, et al. Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. Schizophrenia Bulletin. PMID 28057720 DOI: 10.1093/Schbul/Sbw181 |
0.352 |
|
| 2017 |
Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. PMID 28044008 DOI: 10.1093/Schbul/Sbw171 |
0.34 |
|
| 2017 |
Iwata Y, Nakajima S, Plitman E, Mihashi Y, Caravaggio F, Chung JK, Kim J, Gerretsen P, Mimura M, Remington G, Graff-Guerrero A. SU84. Neurometabolite Levels in Antipsychotic Naive/Free Patients With Schizophrenia: A Meta-Analysis of 1H-MRS Studies. Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx024.080 |
0.414 |
|
| 2017 |
Caravaggio F, Mar W, Remington G, Graff-Guerrero A, Menon M. SA118. Intranasal Oxytocin Does Not Modulate Jumping to Conclusion: S in Schizophrenia: Potential Interaction With Baseline Social Functioning. Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx023.114 |
0.375 |
|
| 2017 |
Silva SD, Saperia S, Apatsidou A, Siddiqui I, Fervaha G, Agid O, Daskalakis Z, Ravindran A, Voineskos A, Zakzanis K, Remington G, Foussias G. SA109. Examining Reward Responsiveness and Expectancy Across a Dimension of Motivation Deficits in Schizophrenia Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx023.107 |
0.434 |
|
| 2017 |
Duncan M, Arbour-Nicitopoulos K, Subramaniapillai MM, Remington G, Faulkner G. M58. Sedentary Behavior Profiles and Obesity Among People With Schizophrenia Schizophrenia Bulletin. 43: S231-S232. DOI: 10.1093/Schbul/Sbx022.055 |
0.365 |
|
| 2017 |
Siddiqui I, Saperia S, Da Silva S, Jeffay E, Pipitone J, Viviano J, Zawadzki J, Wong A, Fervaha G, Agid O, Zakzanis K, Remington G, Voineskos A, Foussias G. 72. Behavioral and Neurobiological Correlates of Attention in Schizophrenia in a Virtual Environment Schizophrenia Bulletin. 43: S42-S42. DOI: 10.1093/Schbul/Sbx021.111 |
0.392 |
|
| 2016 |
Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Focus (American Psychiatric Publishing). 14: 396-402. PMID 31997961 DOI: 10.1176/appi.focus.140306 |
0.333 |
|
| 2016 |
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, ... ... Remington G, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. The American Journal of Psychiatry. appiajp201616050503. PMID 27919182 DOI: 10.1176/Appi.Ajp.2016.16050503 |
0.405 |
|
| 2016 |
Schulze L, Remington G, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J. Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. Journal of Psychopharmacology (Oxford, England). PMID 27852961 DOI: 10.1177/0269881116675516 |
0.307 |
|
| 2016 |
Duncan MJ, Arbour-Nicitopoulos K, Subramanieapillai M, Remington G, Faulkner G. Revisiting the International Physical Activity Questionnaire (IPAQ): Assessing physical activity among individuals with schizophrenia. Schizophrenia Research. PMID 27623360 DOI: 10.1016/J.Schres.2016.09.010 |
0.33 |
|
| 2016 |
Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP, Suridjan I, Wilson AA, Meyer JH, Remington G, Houle S, Rusjan PM, Mizrahi R. Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [(18)F]FEPPA. The American Journal of Psychiatry. appiajp201616020171. PMID 27609240 DOI: 10.1176/Appi.Ajp.2016.16020171 |
0.338 |
|
| 2016 |
Lister J, Andreazza AC, Navaid B, Wilson VS, Teo C, Nesarajah Y, Wilson AA, Nobrega JN, Fletcher PJ, Remington G. Lipoic Acid and Haloperidol-Induced Vacuous Chewing Movements: Implications for Prophylactic Antioxidant Use in Tardive Dyskinesia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 27565433 DOI: 10.1016/J.Pnpbp.2016.08.010 |
0.336 |
|
| 2016 |
Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology. PMID 27557949 DOI: 10.1007/S00213-016-4415-6 |
0.45 |
|
| 2016 |
Takeuchi H, Fervaha G, Remington G. Reliability of a patient-reported outcome measure in schizophrenia: Results from back-to-back self-ratings. Psychiatry Research. 244: 415-419. PMID 27543916 DOI: 10.1016/J.Psychres.2016.07.055 |
0.382 |
|
| 2016 |
Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J, Hahn M. Treating Negative Symptoms in Schizophrenia: an Update. Current Treatment Options in Psychiatry. 3: 133-150. PMID 27376016 DOI: 10.1007/S40501-016-0075-8 |
0.637 |
|
| 2016 |
Duncan MJ, Arbour-Nicitopoulos K, Subramanieapillai M, Remington G, Faulkner G. Comparative Validity of Physical Activity Assessment Methods for Individuals with Schizophrenia: 2695 Board #218 June 3, 11: 00 AM - 12: 30 PM. Medicine and Science in Sports and Exercise. 48: 754. PMID 27361331 DOI: 10.1249/01.Mss.0000487264.76746.F6 |
0.387 |
|
| 2016 |
Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD). Journal of Psychiatric Research. 80: 87-92. PMID 27318892 DOI: 10.1016/J.Jpsychires.2016.06.005 |
0.351 |
|
| 2016 |
Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction and happiness among young adults with schizophrenia. Psychiatry Research. 242: 174-179. PMID 27288735 DOI: 10.1016/J.Psychres.2016.05.046 |
0.45 |
|
| 2016 |
Takeuchi H, Fervaha G, Lee J, Remington G. What symptom domains are associated with patient distress in schizophrenia? Schizophrenia Research. PMID 27261417 DOI: 10.1016/J.Schres.2016.05.020 |
0.413 |
|
| 2016 |
Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology. PMID 27251130 DOI: 10.1007/S00213-016-4324-8 |
0.546 |
|
| 2016 |
Fervaha G, Takeuchi H, Foussias G, Agid O, Remington G. Using poverty of speech as a case study to explore the overlap between negative symptoms and cognitive dysfunction. Schizophrenia Research. PMID 27242067 DOI: 10.1016/J.Schres.2016.05.019 |
0.411 |
|
| 2016 |
Remington G, Lee J, Agid O, Takeuchi H, Foussias G, Hahn M, Fervaha G, Burton L, Powell V. Clozapine's Critical Role in Treatment Resistant Schizophrenia: Ensuring Both Safety and Use. Expert Opinion On Drug Safety. PMID 27207070 DOI: 10.1080/14740338.2016.1191468 |
0.586 |
|
| 2016 |
Oh N, See YM, Remington G, Lee J. Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology. PMID 27187561 DOI: 10.1097/Jcp.0000000000000513 |
0.402 |
|
| 2016 |
Taylor DL, Tiwari AK, Lieberman JA, Potkin SG, Meltzer HY, Knight J, Remington G, Müller DJ, Kennedy JL. Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology. PMID 26876050 DOI: 10.1002/Hup.2519 |
0.435 |
|
| 2016 |
Duncan MJ, Faulkner G, Remington G, Arbour-Nicitopoulos K. Characterizing the affective responses to an acute bout of moderate-intensity exercise among outpatients with schizophrenia. Psychiatry Research. PMID 26851964 DOI: 10.1016/J.Psychres.2016.01.030 |
0.326 |
|
| 2016 |
Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazra M, Wong A, Daskalakis ZJ, Mamo DC. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 77: e14-20. PMID 26845273 DOI: 10.4088/Jcp.14M09321 |
0.449 |
|
| 2016 |
Koga AT, Strauss J, Zai C, Remington G, De Luca V. Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study. Journal of Neural Transmission (Vienna, Austria : 1996). 123: 329-38. PMID 26821981 DOI: 10.1007/S00702-015-1472-7 |
0.365 |
|
| 2015 |
Siu CO, Harvey PD, Agid O, Waye M, Brambilla C, Choi WK, Remington G. Insight and subjective measures of quality of life in chronic schizophrenia. Schizophrenia Research. Cognition. 2: 127-132. PMID 26973810 DOI: 10.1016/J.Scog.2015.05.002 |
0.382 |
|
| 2015 |
Lee J, Takeuchi H, Fervaha G, Sin GL, Foussias G, Agid O, Farooq S, Remington G. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 515-522. PMID 26720509 DOI: 10.1177/070674371506001107 |
0.464 |
|
| 2015 |
Agid O, Mcdonald K, Fervaha G, Littrell R, Thoma J, Zipursky RB, Foussias G, Remington G. Values in First-Episode Schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: 507-14. PMID 26720508 |
0.324 |
|
| 2015 |
Behdinan T, Foussias G, Wheeler AL, Stefanik L, Felsky D, Remington G, Rajji TK, Mallar Chakravarty M, Voineskos AN. Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up. Schizophrenia Research. PMID 26603060 DOI: 10.1016/J.Schres.2015.10.023 |
0.423 |
|
| 2015 |
Lam M, Abdul Rashid NA, Lee SA, Lim J, Foussias G, Fervaha G, Ruhrman S, Remington G, Lee J. Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26553972 DOI: 10.1016/J.Euroneuro.2015.10.007 |
0.391 |
|
| 2015 |
Takeuchi H, Fervaha G, Remington G. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia. Journal of Clinical Psychopharmacology. 35: 728-30. PMID 26479222 DOI: 10.1097/Jcp.0000000000000424 |
0.467 |
|
| 2015 |
Takeuchi H, Remington G. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-Based Mental Health. 18: 117. PMID 26459470 DOI: 10.1136/eb-2015-102209 |
0.351 |
|
| 2015 |
Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G. Measuring motivation in people with schizophrenia. Schizophrenia Research. PMID 26391283 DOI: 10.1016/J.Schres.2015.09.012 |
0.425 |
|
| 2015 |
Fervaha G, Zakzanis KK, Foussias G, Agid O, Remington G. Distress related to subclinical negative symptoms in a non-clinical sample: Role of dysfunctional attitudes. Psychiatry Research. 230: 249-54. PMID 26365687 DOI: 10.1016/J.Psychres.2015.09.002 |
0.314 |
|
| 2015 |
Remington GJ, Teo C, Wilson V, Chintoh A, Guenette M, Ahsan Z, Giacca A, Hahn MK. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance. The Journal of Endocrinology. 227: 71-81. PMID 26330531 DOI: 10.1530/Joe-15-0074 |
0.533 |
|
| 2015 |
Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R, Remington G. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study. Journal of Clinical Psychopharmacology. 35: 510-6. PMID 26267420 DOI: 10.1097/Jcp.0000000000000387 |
0.334 |
|
| 2015 |
Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. PMID 26260899 DOI: 10.1007/S00406-015-0629-6 |
0.424 |
|
| 2015 |
Remington G, Seeman MV. Schizophrenia and the Influence of Male Gender Clinical Pharmacology and Therapeutics. 98: 578-581. PMID 26260896 DOI: 10.1002/Cpt.201 |
0.376 |
|
| 2015 |
Fervaha G, Duncan M, Foussias G, Agid O, Faulkner GE, Remington G. Effort-based decision making as an objective paradigm for the assessment of motivational deficits in schizophrenia. Schizophrenia Research. 168: 483-90. PMID 26215506 DOI: 10.1016/J.Schres.2015.07.023 |
0.443 |
|
| 2015 |
Lockwood JT, Remington G. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Expert Opinion On Emerging Drugs. 20: 407-21. PMID 26166007 DOI: 10.1517/14728214.2015.1050376 |
0.37 |
|
| 2015 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia. Medical Hypotheses. PMID 26118462 DOI: 10.1016/J.Mehy.2015.06.011 |
0.651 |
|
| 2015 |
Foussias G, Siddiqui I, Fervaha G, Mann S, McDonald K, Agid O, Zakzanis KK, Remington G. Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. Schizophrenia Research. 166: 276-82. PMID 26008882 DOI: 10.1016/J.Schres.2015.05.019 |
0.317 |
|
| 2015 |
Fervaha G, Hill C, Agid O, Takeuchi H, Foussias G, Siddiqui I, Kern RS, Remington G. Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. Schizophrenia Research. 166: 304-9. PMID 26004693 DOI: 10.1016/J.Schres.2015.05.015 |
0.369 |
|
| 2015 |
Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophrenia Research. 166: 9-16. PMID 25982811 DOI: 10.1016/J.Schres.2015.04.040 |
0.433 |
|
| 2015 |
Siu CO, Agid O, Remington G. Measuring the effects of treatment with antipsychotics. Jama Psychiatry. 72: 514-5. PMID 25945491 DOI: 10.1001/Jamapsychiatry.2014.3134 |
0.328 |
|
| 2015 |
Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: S14-8. PMID 25886675 |
0.631 |
|
| 2015 |
Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Schizophrenia Research. 164: 149-54. PMID 25864950 DOI: 10.1016/J.Schres.2015.03.025 |
0.462 |
|
| 2015 |
Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, Remington G. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. The American Journal of Psychiatry. 172: 579-85. PMID 25859763 DOI: 10.1176/Appi.Ajp.2015.14050673 |
0.369 |
|
| 2015 |
Lee J, Fervaha G, Takeuchi H, Powell V, Remington G. Positive symptoms are associated with clinicians' global impression in treatment-resistant schizophrenia. Journal of Clinical Psychopharmacology. 35: 237-41. PMID 25839337 DOI: 10.1097/Jcp.0000000000000310 |
0.397 |
|
| 2015 |
Wheeler AL, Wessa M, Szeszko PR, Foussias G, Chakravarty MM, Lerch JP, DeRosse P, Remington G, Mulsant BH, Linke J, Malhotra AK, Voineskos AN. Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. Jama Psychiatry. 72: 446-55. PMID 25786193 DOI: 10.1001/Jamapsychiatry.2014.3020 |
0.441 |
|
| 2015 |
Moriguchi S, Bies RR, Remington G. Erratum: Estimated dopamine D2 Receptor Occupancy and Remission in Schizophrenia. Analysis of the CATIE Data (Journal of Clinical Psychopharmacology (2013) 33 (682-685)) Journal of Clinical Psychopharmacology. 35. PMID 25719960 DOI: 10.1097/01.Jcp.0000462421.30671.09 |
0.424 |
|
| 2015 |
Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18: pyv014. PMID 25716779 DOI: 10.1093/Ijnp/Pyv014 |
0.578 |
|
| 2015 |
Nakajima S, Takeuchi H, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophrenia Research. 164: 164-75. PMID 25684554 DOI: 10.1016/J.Schres.2015.01.043 |
0.453 |
|
| 2015 |
Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Remington G. Relationship between symptomatic improvement and overall illness severity in patients with schizophrenia. Journal of Clinical Psychopharmacology. 35: 128-33. PMID 25679125 DOI: 10.1097/Jcp.0000000000000286 |
0.413 |
|
| 2015 |
Fervaha G, Agid O, Takeuchi H, Foussias G, Lee J, Remington G. Clinical and functional outcomes in people with schizophrenia with a high sense of well-being. The Journal of Nervous and Mental Disease. 203: 187-93. PMID 25668654 DOI: 10.1097/Nmd.0000000000000266 |
0.438 |
|
| 2015 |
Sinyor M, Schaffer A, Remington G. Suicide in schizophrenia: an observational study of coroner records in Toronto. The Journal of Clinical Psychiatry. 76: e98-103. PMID 25650686 DOI: 10.4088/Jcp.14M09047 |
0.402 |
|
| 2015 |
Takeuchi H, Fervaha G, Lee J, Agid O, Remington G. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 295-302. PMID 25649680 DOI: 10.1016/J.Euroneuro.2014.12.008 |
0.424 |
|
| 2015 |
Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G. Antipsychotics and amotivation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1539-48. PMID 25567425 DOI: 10.1038/Npp.2015.3 |
0.487 |
|
| 2015 |
Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. Schizophrenia Research. 161: 429-33. PMID 25556080 DOI: 10.1016/J.Schres.2014.12.024 |
0.445 |
|
| 2015 |
Fervaha G, Agid O, Takeuchi H, Lee J, Foussias G, Zakzanis KK, Graff-Guerrero A, Remington G. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophrenia Research. 161: 351-6. PMID 25471015 DOI: 10.1016/J.Schres.2014.11.018 |
0.45 |
|
| 2015 |
Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, Pollock BG, Graff-Guerrero A. Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominance. Human Brain Mapping. 36: 213-25. PMID 25209949 DOI: 10.1002/Hbm.22624 |
0.365 |
|
| 2015 |
Remington G. Book Review: Extrapyramidal Side Effects: A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Second Edition The Canadian Journal of Psychiatry. 60: 412-412. DOI: 10.1177/070674371506000907 |
0.314 |
|
| 2015 |
Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, MasaruMimura, Uchida H. Corrigendum to Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data [Schizophr. Res. 150 (2-3), November 2013, Pages 373-379], DOI: 10.1016/j.schres.2013.08.033 Schizophrenia Research. 162: 296. DOI: 10.1016/J.Schres.2015.01.011 |
0.41 |
|
| 2015 |
Caravaggio F, Hahn M, Nakajima S, Gerretsen P, Remington G, Graff-Guerrero A. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia Medical Hypotheses. DOI: 10.1016/j.mehy.2015.06.011 |
0.567 |
|
| 2014 |
Fervaha G, Takeuchi H, Agid O, Lee J, Foussias G, Remington G. Determinants of patient-rated and clinician-rated illness severity in schizophrenia. The Journal of Clinical Psychiatry. PMID 25562591 DOI: 10.4088/Jcp.14M09128 |
0.407 |
|
| 2014 |
Gerretsen P, Menon M, Mamo DC, Fervaha G, Remington G, Pollock BG, Graff-Guerrero A. Impaired insight into illness and cognitive insight in schizophrenia spectrum disorders: resting state functional connectivity. Schizophrenia Research. 160: 43-50. PMID 25458571 DOI: 10.1016/J.Schres.2014.10.015 |
0.424 |
|
| 2014 |
Gorczynski P, Faulkner G, Cohn T, Remington G. Examining strategies to improve accelerometer compliance for individuals living with schizophrenia. Psychiatric Rehabilitation Journal. 37: 333-5. PMID 25243343 DOI: 10.1037/Prj0000093 |
0.431 |
|
| 2014 |
Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A. Glutamate-mediated excitotoxicity in schizophrenia: a review. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1591-605. PMID 25159198 DOI: 10.1016/J.Euroneuro.2014.07.015 |
0.443 |
|
| 2014 |
Lee J, Takeuchi H, Fervaha G, Bhaloo A, Powell V, Remington G. Relationship between clinical improvement and functional gains with clozapine in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1622-9. PMID 25156578 DOI: 10.1016/J.Euroneuro.2014.08.003 |
0.382 |
|
| 2014 |
Li CH, Stratford RE, Velez de Mendizabal N, Cremers TI, Pollock BG, Mulsant BH, Remington G, Bies RR. Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. Journal of Translational Medicine. 12: 203. PMID 25142323 DOI: 10.1186/1479-5876-12-203 |
0.315 |
|
| 2014 |
Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H. Dose reduction of risperidone and olanzapine and estimated dopamine Dâ‚‚ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. The Journal of Clinical Psychiatry. 75: 1209-14. PMID 25099201 DOI: 10.4088/Jcp.13M08841 |
0.471 |
|
| 2014 |
Fervaha G, Zakzanis KK, Foussias G, Graff-Guerrero A, Agid O, Remington G. Motivational deficits and cognitive test performance in schizophrenia. Jama Psychiatry. 71: 1058-65. PMID 25075930 DOI: 10.1001/Jamapsychiatry.2014.1105 |
0.414 |
|
| 2014 |
Hettige NC, Zai C, Hazra M, Borlido C, Kennedy JL, Strauss J, Le Foll B, Wong A, Remington G, De Luca V. Use of candidate gene markers to guide antipsychotic dosage adjustment. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 54: 315-20. PMID 25016278 DOI: 10.1016/j.pnpbp.2014.07.001 |
0.336 |
|
| 2014 |
Arbour-Nicitopoulos KP, Duncan M, Remington G, Cairney J, Faulkner GE. Development and Reliability Testing of a Health Action Process Approach Inventory for Physical Activity Participation among Individuals with Schizophrenia. Frontiers in Psychiatry. 5: 68. PMID 24959152 DOI: 10.3389/Fpsyt.2014.00068 |
0.4 |
|
| 2014 |
Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H. Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia. Journal of Clinical Psychopharmacology. 34: 517-20. PMID 24911439 DOI: 10.1097/Jcp.0000000000000142 |
0.437 |
|
| 2014 |
Lee J, Powell V, Remington G. Mean platelet volume in schizophrenia unaltered after 1year of clozapine exposure. Schizophrenia Research. 157: 134-6. PMID 24906221 DOI: 10.1016/J.Schres.2014.04.038 |
0.393 |
|
| 2014 |
Lee J, Takeuchi H, Remington G. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls. Journal of Clinical Psychopharmacology. 34: 530-2. PMID 24875070 DOI: 10.1097/Jcp.0000000000000149 |
0.303 |
|
| 2014 |
Fervaha G, Foussias G, Agid O, Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia Acta Psychiatrica Scandinavica. 130: 290-299. PMID 24850369 DOI: 10.1111/Acps.12289 |
0.428 |
|
| 2014 |
Fervaha G, Agid O, McDonald K, Foussias G, Remington G. Daily activity patterns in remitted first-episode schizophrenia. Comprehensive Psychiatry. 55: 1182-7. PMID 24813789 DOI: 10.1016/J.Comppsych.2014.04.001 |
0.443 |
|
| 2014 |
Lister J, Nobrega JN, Fletcher PJ, Remington G. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology. 231: 2237-49. PMID 24752659 DOI: 10.1007/S00213-014-3582-6 |
0.329 |
|
| 2014 |
Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1078-85. PMID 24726579 DOI: 10.1016/J.Euroneuro.2014.03.001 |
0.43 |
|
| 2014 |
Fervaha G, Foussias G, Siddiqui I, Agid O, Remington G. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures. Schizophrenia Research. 154: 89-92. PMID 24630140 DOI: 10.1016/J.Schres.2014.02.013 |
0.367 |
|
| 2014 |
Remington G, Foussias G, Fervaha G, Agid O. Schizophrenia, cognition, and psychosis. Jama Psychiatry. 71: 336-7. PMID 24599240 DOI: 10.1001/jamapsychiatry.2013.3532 |
0.303 |
|
| 2014 |
Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. The Journal of Clinical Psychiatry. 75: 506-11. PMID 24569099 DOI: 10.4088/Jcp.13M08695 |
0.427 |
|
| 2014 |
Fervaha G, Agid O, Foussias G, Remington G. Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. Journal of Psychiatric Research. 52: 50-6. PMID 24507885 DOI: 10.1016/J.Jpsychires.2014.01.009 |
0.407 |
|
| 2014 |
Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Schizophrenia Research. 153: 184-8. PMID 24491908 DOI: 10.1016/J.Schres.2014.01.017 |
0.455 |
|
| 2014 |
Guenette MD, Chintoh A, Remington G, Hahn M. Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging. 31: 159-84. PMID 24477569 DOI: 10.1007/S40266-014-0152-X |
0.574 |
|
| 2014 |
Remington G, Fervaha G, Foussias G, Agid O, Turrone P. Antipsychotic dosing: found in translation. Journal of Psychiatry & Neuroscience : Jpn. 39: 223-31. PMID 24467943 DOI: 10.1503/Jpn.130191 |
0.793 |
|
| 2014 |
Lee J, Nurjono M, Tay YH, Lee TS, Remington G. A comparison of cardio-metabolic risk between the deficit and non-deficit subtypes of schizophrenia. Schizophrenia Research. 153: 246-7. PMID 24451398 DOI: 10.1016/J.Schres.2014.01.007 |
0.419 |
|
| 2014 |
Lee J, Remington G. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia. The American Journal of Psychiatry. 171: 118-9. PMID 24399431 DOI: 10.1176/Appi.Ajp.2013.13070965 |
0.452 |
|
| 2014 |
Remington G, Hahn M. Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects. Journal of Psychiatry & Neuroscience : Jpn. 39: E1-2. PMID 24359929 DOI: 10.1503/Jpn.130222 |
0.506 |
|
| 2014 |
Fervaha G, Agid O, Foussias G, Remington G. Effect of intrinsic motivation on cognitive performance in schizophrenia: a pilot study. Schizophrenia Research. 152: 317-8. PMID 24333003 DOI: 10.1016/J.Schres.2013.11.037 |
0.415 |
|
| 2014 |
Foussias G, Agid O, Fervaha G, Remington G. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 693-709. PMID 24275699 DOI: 10.1016/J.Euroneuro.2013.10.017 |
0.422 |
|
| 2014 |
Remington G, Foussias G, Agid O, Fervaha G, Takeuchi H, Hahn M. The neurobiology of relapse in schizophrenia. Schizophrenia Research. 152: 381-90. PMID 24206930 DOI: 10.1016/J.Schres.2013.10.009 |
0.653 |
|
| 2014 |
Hahn MK, Chintoh A, Remington G, Teo C, Mann S, Arenovich T, Fletcher P, Lam L, Nobrega J, Guenette M, Cohn T, Giacca A. Effects of intracerebroventricular (ICV) olanzapine on insulin sensitivity and secretion in vivo: an animal model. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 448-58. PMID 24001874 DOI: 10.1016/J.Euroneuro.2013.07.011 |
0.582 |
|
| 2014 |
Fervaha G, Agid O, Foussias G, Graff-Guerrero A, Zakzanis K, Remington G. Poster #T76 BEHAVIOURAL ECONOMICS OF EFFORT-BASED REWARD-DRIVEN CHOICE IN SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70893-X |
0.388 |
|
| 2014 |
Agid O, Fervaha G, McDonald K, Littrell R, Thoma J, Foussias G, Remington E, Siu C, Remington G. Poster #T4 VALUE RECALIBRATION IN FIRST-EPISODE SCHIZOPHRENIA Schizophrenia Research. 153: S290. DOI: 10.1016/S0920-9964(14)70821-7 |
0.404 |
|
| 2014 |
Agid O, Fervaha G, Foussias G, Siu C, McDonald K, Remington G. Poster #M211 THE THREE FACES OF SCHIZOPHRENIA: SUB-TYPING SCHIZOPHRENIA BASED ON RESPONSE AND IMPLICATIONS FOR TREATMENT Schizophrenia Research. 153: S266-S267. DOI: 10.1016/S0920-9964(14)70761-3 |
0.438 |
|
| 2014 |
Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies R, Grönte D, Remington G. Poster #S249 IS ONCE DAILY DOSING OF PERPHENAZINE CLINICALLY FEASIBLE? Schizophrenia Research. 153: S180. DOI: 10.1016/S0920-9964(14)70528-6 |
0.409 |
|
| 2014 |
Agid O, Siu C, Harvey PD, Zipursky R, Fervaha G, Foussias G, McDonald K, Remington G. Poster #S211 TREATMENT OUTCOMES, INSIGHT AND RECOVERY IN FIRST-EPISODE SCHIZOPHRENIA Schizophrenia Research. 153: S165-S166. DOI: 10.1016/S0920-9964(14)70490-6 |
0.427 |
|
| 2014 |
Siu C, Agid O, Waye M, Brambilla C, Choi W, Remington G, Harvey PD. Poster #S102 INSIGHT INTO ILLNESS, COGNITIVE REASONING AND UNCOOPERATIVENESS IN CHRONIC SCHIZOPHRENIA Schizophrenia Research. 153: S125-S126. DOI: 10.1016/S0920-9964(14)70381-0 |
0.404 |
|
| 2014 |
Foussias G, Siddiqui I, McDonald K, Jeffay E, Zawadzki J, Wong A, Agid O, Zakzanis K, Remington G. Poster #S91 ECOLOGICALLY-VALID ASSESSMENT OF ATTENTION IN SCHIZOPHRENIA IN A VIRTUAL ENVIRONMENT Schizophrenia Research. 153: S121. DOI: 10.1016/S0920-9964(14)70370-6 |
0.405 |
|
| 2014 |
Hahn MK, Remington G, Chintoh A, Teo C, Fletcher P, Norbrega J, Guenette M, Cohn T, Giacca A. CLINCIAL INSIGHTS DERIVED FROM RODENT MODELS OF ANTIPSYCHOTIC-INDUCED METABOLIC PERTRUBATIONS Schizophrenia Research. 153: S70. DOI: 10.1016/S0920-9964(14)70226-9 |
0.564 |
|
| 2014 |
Agid O, Siu C, Remington G. PATTERNS OF RESPONSE AND THE NEUROBIOLOGY OF RELAPSE IN SCHIZOPHRENIA Schizophrenia Research. 153: S37. DOI: 10.1016/S0920-9964(14)70122-7 |
0.43 |
|
| 2014 |
Gorczynski P, Faulkner G, Cohn T, Remington G. Examining the efficacy and feasibility of exercise counseling in individuals with schizophrenia: A single-case experimental study Mental Health and Physical Activity. 7: 191-197. DOI: 10.1016/J.Mhpa.2014.04.002 |
0.339 |
|
| 2014 |
Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia European Psychiatry. DOI: 10.1016/J.Eurpsy.2014.01.007 |
0.389 |
|
| 2013 |
Zawadzki JA, Girard TA, Foussias G, Rodrigues A, Siddiqui I, Lerch JP, Grady C, Remington G, Wong AH. Simulating real world functioning in schizophrenia using a naturalistic city environment and single-trial, goal-directed navigation. Frontiers in Behavioral Neuroscience. 7: 180. PMID 24324418 DOI: 10.3389/Fnbeh.2013.00180 |
0.412 |
|
| 2013 |
Siu CO, Agid O, Remington G. Efficacy of antipsychotic drugs for schizophrenia. Lancet (London, England). 382: 1874. PMID 24315169 DOI: 10.1016/S0140-6736(13)62616-1 |
0.441 |
|
| 2013 |
Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study. Schizophrenia Research. 151: 203-8. PMID 24183751 DOI: 10.1016/J.Schres.2013.10.021 |
0.382 |
|
| 2013 |
Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. Journal of Clinical Psychopharmacology. 33: 740-6. PMID 24100786 DOI: 10.1097/Jcp.0B013E31829E8333 |
0.548 |
|
| 2013 |
Farooq S, Agid O, Foussias G, Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophrenia Bulletin. 39: 1169-72. PMID 24045038 DOI: 10.1093/Schbul/Sbt137 |
0.389 |
|
| 2013 |
Fervaha G, Foussias G, Agid O, Remington G. Neural substrates underlying effort computation in schizophrenia. Neuroscience and Biobehavioral Reviews. 37: 2649-65. PMID 24035741 DOI: 10.1016/J.Neubiorev.2013.09.001 |
0.451 |
|
| 2013 |
Fervaha G, Agid O, Takeuchi H, Foussias G, Remington G. Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study. The American Journal of Psychiatry. 170: 1061-2. PMID 24030617 DOI: 10.1176/Appi.Ajp.2013.13010060 |
0.417 |
|
| 2013 |
Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophrenia Research. 150: 373-9. PMID 24028745 DOI: 10.1016/J.Schres.2013.08.033 |
0.402 |
|
| 2013 |
Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. Journal of Psychiatric Research. 47: 1590-6. PMID 23992770 DOI: 10.1016/J.Jpsychires.2013.08.003 |
0.438 |
|
| 2013 |
Chan LF, Zai C, Monda M, Potkin S, Kennedy JL, Remington G, Lieberman J, Meltzer HY, De Luca V. Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics. 14: 1273-81. PMID 23930674 DOI: 10.2217/Pgs.13.127 |
0.322 |
|
| 2013 |
Fervaha G, Foussias G, Agid O, Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Research. 210: 665-8. PMID 23911005 DOI: 10.1016/J.Psychres.2013.07.024 |
0.411 |
|
| 2013 |
Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Journal of Clinical Psychopharmacology. 33: 682-5. PMID 23899638 DOI: 10.1097/Jcp.0B013E3182979A0A |
0.418 |
|
| 2013 |
Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, Zipursky RB, Remington G. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. The American Journal of Psychiatry. 170: 1335-44. PMID 23896810 DOI: 10.1176/Appi.Ajp.2013.12030315 |
0.375 |
|
| 2013 |
Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia Bulletin. 39: 993-8. PMID 23821768 DOI: 10.1093/Schbul/Sbt090 |
0.44 |
|
| 2013 |
Takeuchi H, Remington G. A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. Psychopharmacology. 228: 175-85. PMID 23736279 DOI: 10.1007/s00213-013-3154-1 |
0.304 |
|
| 2013 |
Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, Takeuchi H, Remington G. Risk of neutropenia in a clozapine-treated elderly population. Schizophrenia Research. 148: 183-5. PMID 23727216 DOI: 10.1016/J.Schres.2013.05.001 |
0.518 |
|
| 2013 |
Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, Fervaha G, Remington G. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1017-22. PMID 23706529 DOI: 10.1016/J.Euroneuro.2013.04.010 |
0.451 |
|
| 2013 |
Rao NP, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials Expert Opinion On Investigational Drugs. 22: 881-894. PMID 23639138 DOI: 10.1517/13543784.2013.795945 |
0.359 |
|
| 2013 |
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, Arenovich T, Remington G. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophrenia Research. 146: 162-9. PMID 23499243 DOI: 10.1016/J.Schres.2013.02.023 |
0.585 |
|
| 2013 |
Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH. Neuroimaging evidence for the deficit subtype of schizophrenia. Jama Psychiatry. 70: 472-80. PMID 23467781 DOI: 10.1001/Jamapsychiatry.2013.786 |
0.459 |
|
| 2013 |
Remington G, Teo C, Mann S, Hahn M, Foussias G, Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. Journal of Clinical Psychopharmacology. 33: 261-3. PMID 23422390 DOI: 10.1097/Jcp.0B013E31828568Bc |
0.583 |
|
| 2013 |
Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z, Mamo D. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology. 228: 43-51. PMID 23417515 DOI: 10.1007/S00213-013-3012-1 |
0.329 |
|
| 2013 |
Remington G, Agid O, Foussias G, Hahn M, Rao N, Sinyor M. Clozapine's role in the treatment of first-episode schizophrenia. The American Journal of Psychiatry. 170: 146-51. PMID 23377634 DOI: 10.1176/Appi.Ajp.2012.12060778 |
0.644 |
|
| 2013 |
Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 226: 1-12. PMID 23344556 DOI: 10.1007/S00213-013-2982-3 |
0.489 |
|
| 2013 |
Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters. Clinical Schizophrenia & Related Psychoses. 6: 186-96. PMID 23302448 DOI: 10.3371/Csrp.Haco.01062013 |
0.674 |
|
| 2013 |
Fervaha G, Remington G. Validation of an abbreviated quality of life scale for schizophrenia European Neuropsychopharmacology. 23: 1072-1077. PMID 23235268 DOI: 10.1016/J.Euroneuro.2012.11.009 |
0.331 |
|
| 2013 |
Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacology, Biochemistry, and Behavior. 103: 717-22. PMID 23234835 DOI: 10.1016/J.Pbb.2012.12.002 |
0.572 |
|
| 2013 |
Fervaha G, Remington G. Neuroimaging findings in schizotypal personality disorder: A systematic review Progress in Neuro-Psychopharmacology and Biological Psychiatry. 43: 96-107. PMID 23220094 DOI: 10.1016/J.Pnpbp.2012.11.014 |
0.467 |
|
| 2012 |
Agid O, Siu CO, Pappadopulos E, Vanderburg D, Remington G. Early prediction of clinical and functional outcome in schizophrenia. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 842-51. PMID 23141372 DOI: 10.1016/J.Euroneuro.2012.10.005 |
0.378 |
|
| 2012 |
Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: Implications for dopamine D 2 receptor occupancy during maintenance treatment in schizophrenia Journal of Clinical Psychiatry. 73: 1147-1152. PMID 22967779 DOI: 10.4088/Jcp.12M07638 |
0.442 |
|
| 2012 |
Agid O, Remington G. Review: maintenance antipsychotics prevent relapse in patients with schizophrenia. Evidence-Based Mental Health. 15: 92. PMID 22904562 DOI: 10.1136/ebmental-2012-100906 |
0.355 |
|
| 2012 |
Agid O, McDonald K, Siu C, Tsoutsoulas C, Wass C, Zipursky RB, Foussias G, Remington G. Happiness in first-episode schizophrenia. Schizophrenia Research. 141: 98-103. PMID 22901593 DOI: 10.1016/J.Schres.2012.07.012 |
0.45 |
|
| 2012 |
Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ. Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophrenia Research. 140: 214-20. PMID 22795368 DOI: 10.1016/J.Schres.2012.06.027 |
0.464 |
|
| 2012 |
Seeman P, Remington G. Antipsychotic dosing: Extended, and transient Clinical Schizophrenia and Related Psychoses. 6: 86-87. PMID 22776635 DOI: 10.3371/Csrp.6.2.6 |
0.46 |
|
| 2012 |
Gohlke JM, Dhurandhar EJ, Correll CU, Morrato EH, Newcomer JW, Remington G, Nasrallah HA, Crystal S, Nicol G, Allison DB. Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry. 3: 62. PMID 22754543 DOI: 10.3389/Fpsyt.2012.00062 |
0.332 |
|
| 2012 |
Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, Mimura M, Mamo DC. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Research. 197: 1-6. PMID 22429484 DOI: 10.1016/J.Psychres.2012.02.013 |
0.444 |
|
| 2012 |
Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 37: 182-7. PMID 22230651 DOI: 10.1016/J.Pnpbp.2011.12.013 |
0.441 |
|
| 2012 |
Remington G, Kapur S, Foussias G, Agid O, Mann S, Borlido C, Richards S, Javaid N. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 32: 95-9. PMID 22198452 DOI: 10.1097/Jcp.0B013E31823F913E |
0.487 |
|
| 2012 |
Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. The American Journal of Psychiatry. 169: 389-96. PMID 22193527 DOI: 10.1176/Appi.Ajp.2011.10070937 |
0.339 |
|
| 2012 |
Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 199: 275-80. PMID 22187729 DOI: 10.1192/Bjp.Bp.110.083907 |
0.451 |
|
| 2012 |
Fervaha G, Remington G. Interpreting a multivariate analysis of functional neuroimaging data Frontiers in Psychiatry. 3. DOI: 10.3389/Fpsyt.2012.00052 |
0.321 |
|
| 2012 |
Hahn MK, Arenovich T, Wolever T, Giacca A, Cohn T, McIntyre R, Teo C, Clarke L, Powell V, Chintoh A, Mann S, Gomes S, Remington G. Poster #223 SINGLE DOSE ADMINISTRATION OF OLANZAPINE: EFFECTS ON GLUCOSE METABOLISM, ENDOCRINE AND INFLAMMATORY MARKERS IN HEALTHY VOLUNTEERS Schizophrenia Research. 136: S266. DOI: 10.1016/S0920-9964(12)70794-6 |
0.558 |
|
| 2012 |
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh AF, Arenovich T, Remington G. Poster #13 RECEPTOR BINDING PROFILES OF ANTIPSYCHOTIC MEDICATIONS AND GLUCOSE DYSREGULATION: AN ACUTE ANIMAL MODEL Schizophrenia Research. 136: S189. DOI: 10.1016/S0920-9964(12)70585-6 |
0.567 |
|
| 2012 |
Agid O, Siu CO, Zipursky RB, Remington G. Poster #203 TIME COURSE OF DROPOUT RATES IN SCHIZOPHRENIA TRIALS CONDUCTED FROM 1966 TO 2010: A SYSTEMATIC REVIEW AND META-ANALYSIS Schizophrenia Research. 136: S164. DOI: 10.1016/S0920-9964(12)70517-0 |
0.399 |
|
| 2012 |
Fervaha G, Teo C, Mann S, Hahn M, Foussias G, Agid O, Remington G. Poster #195 EXAMINING LEVELS OF ANTIPSYCHOTIC ADHERENCE TO BETTER UNDERSTAND NONADHERENCE IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 136: S161. DOI: 10.1016/S0920-9964(12)70509-1 |
0.662 |
|
| 2012 |
Agid O, Siu CO, McDonald K, Tsoutsoulasl C, Wass C, Foussias G, Remington G. 15:30 ARE PATIENTS WITH SCHIZOPHRENIA HAPPY? Schizophrenia Research. 136: S80. DOI: 10.1016/S0920-9964(12)70288-8 |
0.448 |
|
| 2011 |
Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs & Aging. 28: 961-980. PMID 22117095 DOI: 10.2165/11595830-000000000-00000 |
0.461 |
|
| 2011 |
Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophrenia Research. 133: 54-62. PMID 22000940 DOI: 10.1016/J.Schres.2011.09.016 |
0.442 |
|
| 2011 |
Potkin S, Agid O, Siu C, Watsky E, Vanderburg D, Remington G. Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia. Schizophrenia Research. 132: 108-13. PMID 21873032 DOI: 10.1016/J.Schres.2011.07.028 |
0.362 |
|
| 2011 |
Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacology, Biochemistry, and Behavior. 100: 86-9. PMID 21839766 DOI: 10.1016/J.Pbb.2011.07.019 |
0.56 |
|
| 2011 |
Menon M, Schmitz TW, Anderson AK, Graff A, Korostil M, Mamo D, Gerretsen P, Addington J, Remington G, Kapur S. Exploring the neural correlates of delusions of reference. Biological Psychiatry. 70: 1127-33. PMID 21831358 DOI: 10.1016/J.Biopsych.2011.05.037 |
0.385 |
|
| 2011 |
Foussias G, Mann S, Zakzanis KK, Reekum Rv, Agid O, Remington G. Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits Schizophrenia Research. 132: 24-27. PMID 21771567 DOI: 10.1016/J.Schres.2011.06.026 |
0.433 |
|
| 2011 |
Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, Fletcher P, Guenette M, Cohn T, Wolever T, Arenovich T, Remington G. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophrenia Research. 131: 90-5. PMID 21696923 DOI: 10.1097/01.Yic.0000405882.94837.86 |
0.592 |
|
| 2011 |
Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington G, Wilson AA, Kapur S. Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research. 131: 63-68. PMID 21684721 DOI: 10.1016/J.Schres.2011.05.005 |
0.411 |
|
| 2011 |
Remington G, Agid O, Foussias G. Schizophrenia as a disorder of too little dopamine: Implications for symptoms and treatment Expert Review of Neurotherapeutics. 11: 589-607. PMID 21469931 DOI: 10.1586/ern.10.191 |
0.375 |
|
| 2011 |
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. The Journal of Clinical Psychiatry. 72: 1439-44. PMID 21457676 DOI: 10.4088/Jcp.09M05785Yel |
0.437 |
|
| 2011 |
Souza RP, Meltzer HY, Lieberman JA, Voineskos AN, Remington G, Kennedy JL. Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. Human Psychopharmacology. 26: 21-7. PMID 21305610 DOI: 10.1002/Hup.1161 |
0.376 |
|
| 2011 |
Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: A double-blind, placebo-controlled trial Journal of Clinical Psychiatry. 72: 1042-1048. PMID 20868639 DOI: 10.4088/JCP.09m05866yel |
0.342 |
|
| 2011 |
Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, Wong AH. Lack of association of NALCN genetic variants with schizophrenia. Psychiatry Research. 185: 450-2. PMID 20674038 DOI: 10.1016/J.Psychres.2010.07.009 |
0.42 |
|
| 2011 |
Hahn M, Chintoh A, Remington G, Fletcher P, Cohn T, Lam L, Mann S, Teo C, Giacca A. P.3.c.008 Intracerebroventricular olanzapine acutely suppresses b-cell secretion in vivo: an animal model European Neuropsychopharmacology. 21: S472. DOI: 10.1016/S0924-977X(11)70765-9 |
0.46 |
|
| 2010 |
Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Journal of Clinical Psychopharmacology. 30: 706-10. PMID 21105286 DOI: 10.1097/Jcp.0B013E3181Fab67D |
0.658 |
|
| 2010 |
Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: Re-examining the evidence Canadian Journal of Psychiatry. 55: 677-684. PMID 20964947 DOI: 10.1177/070674371005501007 |
0.458 |
|
| 2010 |
Remington G, Kapur S. Antipsychotic dosing: How much but also how often? Schizophrenia Bulletin. 36: 900-903. PMID 20650931 DOI: 10.1093/Schbul/Sbq083 |
0.401 |
|
| 2010 |
Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, Pollock BG, Mulsant BH. Clozapine and global cognition in schizophrenia. Journal of Clinical Psychopharmacology. 30: 431-6. PMID 20631560 DOI: 10.1097/Jcp.0B013E3181E69060 |
0.424 |
|
| 2010 |
Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Determining rates of hepatitis C in a clozapine treated cohort. Schizophrenia Research. 124: 86-90. PMID 20605572 DOI: 10.1016/J.Schres.2010.06.005 |
0.351 |
|
| 2010 |
Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 688-94. PMID 20605420 DOI: 10.1016/J.Euroneuro.2010.05.002 |
0.307 |
|
| 2010 |
Hahn MK, Cohn T, Remington G. Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. The Annals of Pharmacotherapy. 44: 1349-50; author repl. PMID 20587740 DOI: 10.1345/aph.1M550a |
0.524 |
|
| 2010 |
Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: Their role in relapse prevention Expert Opinion On Pharmacotherapy. 11: 2301-2317. PMID 20586707 DOI: 10.1517/14656566.2010.499125 |
0.357 |
|
| 2010 |
Remington G. Antipsychotic dosing: Still a work in progress American Journal of Psychiatry. 167: 623-625. PMID 20516160 DOI: 10.1176/Appi.Ajp.2010.10030302 |
0.312 |
|
| 2010 |
Souza RP, Remington G, Meltzer HY, Lieberman JA, Kennedy JL, Wong AH. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. International Clinical Psychopharmacology. 25: 264-9. PMID 20436352 DOI: 10.1016/J.Schres.2010.02.586 |
0.376 |
|
| 2010 |
Foussias G, Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making Canadian Journal of Psychiatry. 55: 117-125. PMID 20370961 |
0.374 |
|
| 2010 |
Foussias G, Mann S, Zakzanis KK, van Reekum R, Remington G. Motivational deficits as the central link to functioning in schizophrenia: a pilot study. Schizophrenia Research. 115: 333-7. PMID 19836211 DOI: 10.1016/J.Schres.2009.09.020 |
0.421 |
|
| 2010 |
Foussias G, Remington G. Negative symptoms in schizophrenia: Avolition and occam's razor Schizophrenia Bulletin. 36: 359-369. PMID 18644851 DOI: 10.1093/Schbul/Sbn094 |
0.426 |
|
| 2010 |
Remington G. Augmenting clozapine response in treatment-resistant schizophrenia Therapy-Resistant Schizophrenia. 26: 129-151. DOI: 10.1159/000319813 |
0.326 |
|
| 2010 |
Hahn M, Chintoh A, Lam L, Mann S, Giacca A, Fletcher P, Remington G. P.3.f.007 Atypical antipsychotics and effects of muscarinic and serotonergic receptor binding on insulin secretion in a rat model European Neuropsychopharmacology. 20: S517. DOI: 10.1016/S0924-977X(10)70772-0 |
0.513 |
|
| 2010 |
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, Remington G. ALGORITHM-BASED TREATMENT OF FIRST-EPISODE SCHIZOPHRENIA: RESPONSE RATES OVER THREE SECOND-GENERATION ANTIPSYCHOTIC TRIALS Schizophrenia Research. 117: 373. DOI: 10.1016/J.Schres.2010.02.666 |
0.422 |
|
| 2010 |
Foussias G, Mann S, Zakzanis KK, van Reekum R, Agid O, Remington G. MOTIVATIONAL DEFICITS IN SCHIZOPHRENIA: CROSS-SECTIONAL AND LONGITUDINAL RELATIONSHIPS WITH FUNCTIONING Schizophrenia Research. 117: 303-304. DOI: 10.1016/J.Schres.2010.02.506 |
0.387 |
|
| 2010 |
Mizrahi R, Addington J, Rusjan P, Ivonne S, Isabelle B, Ng A, Pruessner J, Remington G, Houle S, Wilson AA. STRESS-INDUCED DOPAMINE RELEASE IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS AND IN ANTIPSYCHOTIC NAIVE PATIENTS WITH PSYCHOSIS: A [11C]-(+)-PHNO PET STUDY Schizophrenia Research. 117: 173-174. DOI: 10.1016/J.Schres.2010.02.204 |
0.331 |
|
| 2009 |
Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, Remington G. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophrenia Research. 108: 127-33. PMID 19157785 DOI: 10.1016/J.Schres.2008.12.012 |
0.419 |
|
| 2009 |
Chintoh AF, Mann SW, Lam TK, Giacca A, Remington G. Insulin resistance following continuous, chronic olanzapine treatment: an animal model. Schizophrenia Research. 104: 23-30. PMID 18675538 DOI: 10.1016/J.Schres.2008.06.006 |
0.333 |
|
| 2009 |
Sockalingam S, Shammi C, Remington G. Treatment of clozapine-induced hypersalivation with ipratropium bromide: A randomized, double-blind, placebo-controlled crossover study Journal of Clinical Psychiatry. 70: 1114-1119. DOI: 10.4088/Jcp.08M04495 |
0.319 |
|
| 2008 |
Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology. 28: 494-9. PMID 18794643 DOI: 10.1097/Jcp.0B013E318184B4C5 |
0.323 |
|
| 2008 |
Remington G. Alterations of dopamine and serotonin transmission in schizophrenia Progress in Brain Research. 172: 117-140. PMID 18772030 DOI: 10.1016/S0079-6123(08)00906-0 |
0.432 |
|
| 2008 |
Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia Expert Opinion On Emerging Drugs. 13: 479-495. PMID 18764724 DOI: 10.1517/14728214.13.3.479 |
0.367 |
|
| 2008 |
Seeman MV, Clodman D, Remington G. Transient tardive dystonia: overview and case presentation. Journal of Psychiatric Practice. 14: 251-7. PMID 18664896 DOI: 10.1097/01.Pra.0000327317.34647.28 |
0.35 |
|
| 2008 |
Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJ, Mann SW, Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. The Journal of Clinical Psychiatry. 69: 1281-6. PMID 18642974 DOI: 10.4088/Jcp.V69N0811 |
0.42 |
|
| 2008 |
Mizrahi R, Addington J, Remington G, Kapur S. Attribution style as a factor in psychosis and symptom resolution Schizophrenia Research. 104: 220-227. PMID 18632256 DOI: 10.1016/J.Schres.2008.05.003 |
0.4 |
|
| 2008 |
Hazra M, Mamo DC, Remington G. Adjunctive versus monotherapeutic treatment for schizophrenia: Addressing antipsychotic side effects American Journal of Psychiatry. 165: 396-397. PMID 18316434 DOI: 10.1176/Appi.Ajp.2007.07111738 |
0.475 |
|
| 2008 |
Remington G, Kapur S. The Pharmacology of Typical and Atypical Antipsychotics Drug Induced Movement Disorders: Second Edition. 55-71. DOI: 10.1002/9780470753217.ch4 |
0.338 |
|
| 2007 |
Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. Molecular Psychiatry. 12: 1058-60. PMID 18043709 DOI: 10.1038/Sj.Mp.4002092 |
0.428 |
|
| 2007 |
Zai CC, De Luca V, Hwang RW, Voineskos A, Müller DJ, Remington G, Kennedy JL. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular Psychiatry. 12: 794-5. PMID 17767146 DOI: 10.1038/Sj.Mp.4002023 |
0.306 |
|
| 2007 |
Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: A review of treatment strategies Canadian Journal of Psychiatry. 52: 377-384. PMID 17696024 DOI: 10.1177/070674370705200607 |
0.365 |
|
| 2007 |
Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. Journal of Clinical Psychopharmacology. 27: 369-73. PMID 17632221 DOI: 10.1097/Jcp.0B013E3180D0A6D4 |
0.45 |
|
| 2007 |
Remington G. Tardive dyskinesia: Eliminated, forgotten, or overshadowed? Current Opinion in Psychiatry. 20: 131-137. PMID 17278910 DOI: 10.1097/Yco.0B013E328017F6B1 |
0.405 |
|
| 2007 |
Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophrenia Research. 90: 229-37. PMID 17208414 DOI: 10.1016/J.Schres.2006.11.015 |
0.451 |
|
| 2006 |
Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: Is there a silver lining? American Journal of Psychiatry. 163: 1132-1134. PMID 16816213 DOI: 10.1176/Appi.Ajp.163.7.1132 |
0.418 |
|
| 2006 |
Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 51: 382-6. PMID 16786820 DOI: 10.1177/070674370605100608 |
0.42 |
|
| 2006 |
Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood Schizophrenia Research. 85: 222-231. PMID 16679001 DOI: 10.1016/J.Schres.2006.03.033 |
0.346 |
|
| 2006 |
Remington G, Saha A, Chong SA, Shammi C. Augmenting strategies in clozapine-resistant schizophrenia Cns Drugs. 20: 171. PMID 16478292 DOI: 10.2165/00023210-200620020-00008 |
0.317 |
|
| 2006 |
Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia Schizophrenia Research. 82: 225-231. PMID 16360305 DOI: 10.1016/J.Schres.2005.10.020 |
0.341 |
|
| 2006 |
Remington G, Seeman P, Shammi C, Mann S, Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. Journal of Clinical Psychopharmacology. 25: 611-3. PMID 16282851 DOI: 10.1097/01.Jcp.0000185341.55096.65 |
0.313 |
|
| 2005 |
Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia Cns Drugs. 19: 843-872. PMID 16185094 DOI: 10.2165/00023210-200519100-00004 |
0.44 |
|
| 2005 |
Potkin SG, Gharabawi GM, Greenspan AJ, Rupnow MF, Kosik-Gonzalez C, Remington G, Ruetsch C, Revicki D. Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophrenia Research. 80: 203-12. PMID 16102943 DOI: 10.1016/J.Schres.2005.06.021 |
0.36 |
|
| 2005 |
Remington G. Rational pharmacotherapy in early psychosis British Journal of Psychiatry. 187. PMID 16055813 DOI: 10.1192/bjp.187.48.s77 |
0.326 |
|
| 2005 |
Chung C, Remington G. Predictors and markers of clozapine response Psychopharmacology. 179: 317-335. PMID 15717209 DOI: 10.1007/S00213-005-2174-X |
0.362 |
|
| 2005 |
Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biological Psychiatry. 57: 406-11. PMID 15705357 DOI: 10.1016/J.Biopsych.2004.10.023 |
0.784 |
|
| 2005 |
Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety. 13: 811-6. PMID 15386706 DOI: 10.1002/pds.978 |
0.318 |
|
| 2004 |
Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 49: 753-60. PMID 15633853 DOI: 10.1177/070674370404901106 |
0.349 |
|
| 2004 |
Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. The American Journal of Psychiatry. 161: 1620-5. PMID 15337652 DOI: 10.1176/Appi.Ajp.161.9.1620 |
0.415 |
|
| 2004 |
Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia Cns Spectrums. 9: 579-586. PMID 15273650 DOI: 10.1017/S1092852900002741 |
0.418 |
|
| 2004 |
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. The American Journal of Psychiatry. 161: 818-25. PMID 15121646 DOI: 10.1176/Appi.Ajp.161.5.818 |
0.359 |
|
| 2004 |
Mamo D, Remington G, Nobrega J, Hussey D, Chirakal R, Wilson AA, Baker G, Houle S, Kapur S. Effect of acute antipsychotic administration on dopamine synthesis in rodents and human subjects using 6-[18F]-L-m-tyrosine. Synapse (New York, N.Y.). 52: 153-62. PMID 15034921 DOI: 10.1002/Syn.20016 |
0.32 |
|
| 2004 |
Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. The Journal of Clinical Psychiatry. 64: 1250-7. PMID 14658976 DOI: 10.4088/Jcp.V64N1017 |
0.404 |
|
| 2004 |
Chue P, Stip E, Remington G, Kopala L. Switching atypical antipsychotics: A review Acta Neuropsychiatrica. 16: 301-313. DOI: 10.1111/J.0924-2708.2004.00098.X |
0.371 |
|
| 2004 |
Kapur S, Sridhar N, Remington G. The newer antipsychotics: Underlying mechanisms and the new clinical realities Current Opinion in Psychiatry. 17: 115-121. DOI: 10.1097/00001504-200403000-00008 |
0.421 |
|
| 2004 |
Faulkner G, Cohn T, Remington G. Interventions to control weight gain in schizophrenia Cochrane Database of Systematic Reviews. DOI: 10.1002/14651858.Cd005148 |
0.396 |
|
| 2003 |
Remington G. Understanding antipsychotic "atypicality": A clinical and pharmacological moving target Journal of Psychiatry and Neuroscience. 28: 275-284. PMID 12921222 |
0.365 |
|
| 2003 |
Kiang M, Christensen BK, Remington G, Kapur S. Apathy in schizophrenia: Clinical correlates and association with functional outcome Schizophrenia Research. 63: 79-88. PMID 12892861 DOI: 10.1016/S0920-9964(02)00433-4 |
0.314 |
|
| 2003 |
Turrone P, Remington G, Kapur S, Nobrega JN. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1433-9. PMID 12838271 DOI: 10.1038/Sj.Npp.1300233 |
0.776 |
|
| 2003 |
Turrone P, Remington G, Kapur S, Nobrega JN. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology. 165: 166-71. PMID 12417967 DOI: 10.1007/S00213-002-1259-Z |
0.782 |
|
| 2003 |
Turrone P, Remington G, Kapur S, Nobrega J. Differential effects of sustained versus transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats Schizophrenia Research. 60: 368. DOI: 10.1016/S0920-9964(03)80204-9 |
0.771 |
|
| 2002 |
Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P. How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. Clinical Therapeutics. 24: 1466-76. PMID 12380638 DOI: 10.1016/S0149-2918(02)80050-9 |
0.397 |
|
| 2002 |
Remington G, Kapur S. Review: amisulpride is effective and safe for schizophrenia. Evidence-Based Mental Health. 5: 85. PMID 12180452 DOI: 10.1136/ebmh.5.3.85 |
0.345 |
|
| 2002 |
Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neuroscience and Biobehavioral Reviews. 26: 361-80. PMID 12034136 DOI: 10.1016/S0149-7634(02)00008-8 |
0.794 |
|
| 2002 |
Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Molecular Psychiatry. 7: 317-21. PMID 11920159 DOI: 10.1038/Sj.Mp.4001009 |
0.316 |
|
| 2002 |
Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. Journal of Clinical Psychopharmacology. 22: 20-5. PMID 11799338 DOI: 10.1097/00004714-200202000-00004 |
0.391 |
|
| 2002 |
Koren G, Cohn T, Chitayat D, Kapur B, Remington G, Reid DM, Zipursky RB. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. The American Journal of Psychiatry. 159: 136-7. PMID 11772703 DOI: 10.1176/Appi.Ajp.159.1.136 |
0.339 |
|
| 2002 |
Remington G, Kapur S. Review: Amisulpride is effective and safe for schizophrenia - Commentary Evidence-Based Mental Health. 5: 85. DOI: 10.1136/Ebmh.5.3.85 |
0.453 |
|
| 2001 |
Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient Biological Psychiatry. 50: 873-883. PMID 11743942 DOI: 10.1016/S0006-3223(01)01251-3 |
0.437 |
|
| 2001 |
Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. The American Journal of Psychiatry. 158: 1305-13. PMID 11481167 DOI: 10.1176/Appi.Ajp.158.8.1305 |
0.454 |
|
| 2001 |
Chong SA, Remington G, Mahendran R, Chua HC. Awareness of tardive dyskinesia in Asian patients with schizophrenia. Journal of Clinical Psychopharmacology. 21: 235-7. PMID 11270922 DOI: 10.1097/00004714-200104000-00017 |
0.396 |
|
| 2001 |
Kapur S, Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia Annual Review of Medicine. 52: 503-517. PMID 11160792 DOI: 10.1146/Annurev.Med.52.1.503 |
0.499 |
|
| 2001 |
Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. The American Journal of Psychiatry. 158: 311-4. PMID 11156818 DOI: 10.1176/Appi.Ajp.158.2.311 |
0.408 |
|
| 2001 |
Remington G, Shammi CM, Sethana R, Lawrence R. Antipsychotic dosing patterns for schizophrenia in three treatment settings Psychiatric Services. 52: 96-98. PMID 11141536 DOI: 10.1176/Appi.Ps.52.1.96 |
0.345 |
|
| 2001 |
Kapur S, Remington G. Atypical antipsychotics. Bmj (Clinical Research Ed.). 321: 1360-1. PMID 11099266 DOI: 10.1136/Bmj.321.7273.1360 |
0.404 |
|
| 2001 |
Remington G. Psychopharmacology of Antipsychotics Psychopharmacology of Antidepressants American Journal of Psychiatry. 158: 1538-1538. DOI: 10.1176/Appi.Ajp.158.9.1538 |
0.395 |
|
| 2001 |
Remington G. Intramuscular ziprasidone reduced symptoms and was well tolerated in acute psychosis: Commentary Evidence-Based Mental Health. 4: 74. DOI: 10.1136/Ebmh.4.3.74 |
0.324 |
|
| 2000 |
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Archives of General Psychiatry. 57: 553-9. PMID 10839333 DOI: 10.1001/Archpsyc.57.6.553 |
0.418 |
|
| 2000 |
Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology. 149: 1-5. PMID 10789875 DOI: 10.1007/S002139900333 |
0.32 |
|
| 2000 |
Kapur S, Wadenberg ML, Remington G. Are animal studies of antipsychotics appropriately dosed?: Lessons from the bedside to the bench Canadian Journal of Psychiatry. 45: 241-246. PMID 10779880 DOI: 10.1177/070674370004500302 |
0.351 |
|
| 2000 |
Remington G. Schizophrenia: Building and fixing scientific models Canadian Journal of Psychiatry. 45: 239-240. PMID 10779879 |
0.319 |
|
| 2000 |
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. The American Journal of Psychiatry. 157: 514-20. PMID 10739409 DOI: 10.1176/Appi.Ajp.157.4.514 |
0.406 |
|
| 2000 |
Remington G. Review: Zotepine was as effective as typical and other atypical antipsychotics and more effective than placebo in schizophrenia: Commentary Evidence-Based Mental Health. 3: 78. DOI: 10.1136/Ebmh.3.3.78 |
0.471 |
|
| 2000 |
Kapur S, Wadenberg M, Remington G. 53. Are animal studies of antipsychotics appropriately dosed? Lessons from bedside to bench Biological Psychiatry. 47: S16. DOI: 10.1016/S0006-3223(00)00315-2 |
0.326 |
|
| 1999 |
Remington G, Chong SA. Conventional versus novel antipsychotics: Changing concepts and clinical implications Journal of Psychiatry and Neuroscience. 24: 431-441. PMID 10586534 |
0.383 |
|
| 1999 |
Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia American Journal of Psychiatry. 156: 286-293. PMID 9989565 DOI: 10.1176/Ajp.156.2.286 |
0.413 |
|
| 1998 |
Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia British Journal of Psychiatry. 172: 66-70. PMID 9764129 DOI: 10.1192/S0007125000297687 |
0.489 |
|
| 1998 |
Remington G, Kapur S, Zipursky R. APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association. The American Journal of Psychiatry. 155: 1301-2. PMID 9734565 DOI: 10.1176/Ajp.155.9.1301A |
0.413 |
|
| 1998 |
Kapur S, Zipursky RB, Remington G, Meltzer H. Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy [3] (multiple letters) Archives of General Psychiatry. 55: 666-668. PMID 9672060 DOI: 10.1001/Archpsyc.55.7.666 |
0.334 |
|
| 1998 |
Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. The American Journal of Psychiatry. 155: 921-8. PMID 9659858 DOI: 10.1176/Ajp.155.7.921 |
0.441 |
|
| 1998 |
Primeau FJ, Remington G. Evidence through Clinical Experience with Novel Antipsychotics The Canadian Journal of Psychiatry. 43. DOI: 10.1177/07067437980430S101 |
0.311 |
|
| 1997 |
Collins AA, Remington GJ, Coulter K, Birkett K. Insight, neurocognitive function and symptom clusters in chronic schizophrenia Schizophrenia Research. 27: 37-44. PMID 9373893 DOI: 10.1016/S0920-9964(97)00075-3 |
0.34 |
|
| 1997 |
Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. The American Journal of Psychiatry. 154: 1525-9. PMID 9356559 DOI: 10.1176/Ajp.154.11.1525 |
0.345 |
|
| 1997 |
Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 131: 148-52. PMID 9201802 DOI: 10.1007/S002130050277 |
0.307 |
|
| 1997 |
Remington G. Book Review: Schizophrenia: Critical Issues in the Treatment of SchizophreniaCritical Issues in the Treatment of Schizophrenia. BrunelloN, RacagniG, LangerSZ, MendlewiczJ, editors. Basel: Karger; 1995. 205 p. US$198.25. The Canadian Journal of Psychiatry. 42: 876-876. DOI: 10.1177/070674379704200812 |
0.451 |
|
| 1996 |
Collins AA, Remington G, Coulter K, Birkett K. Depression in schizophrenia: A comparison of three measures Schizophrenia Research. 20: 205-209. PMID 8794511 DOI: 10.1016/0920-9964(95)00107-7 |
0.334 |
|
| 1996 |
Remington GJ, Addington D, Collins EJ, Jones BD, Lalonde P, MacCrimmon DJ, MacEwan GW. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 41: 161-6. PMID 8722645 DOI: 10.1177/070674379604100306 |
0.351 |
|
| 1996 |
Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. The American Journal of Psychiatry. 153: 948-50. PMID 8659621 DOI: 10.1176/Ajp.153.7.948 |
0.346 |
|
| 1996 |
Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia American Journal of Psychiatry. 153: 466-476. PMID 8599393 DOI: 10.1176/Ajp.153.4.466 |
0.423 |
|
| 1996 |
Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes Cns Drugs. 5: 21-35. DOI: 10.2165/00023210-199600051-00005 |
0.349 |
|
| 1996 |
Remington G. First episode psychosis: Diagnosis, treatment and the role of new antipsychotics European Neuropsychopharmacology. 6: 33. DOI: 10.1016/0924-977X(96)87450-5 |
0.346 |
|
| 1995 |
Remington G. Understanding schizophrenia: The impact of novel antipsychotics Canadian Journal of Psychiatry. 40. PMID 8564914 DOI: 10.1177/070674379504007S01 |
0.464 |
|
| 1995 |
Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sciences. 57: PL103-7. PMID 7543969 DOI: 10.1016/0024-3205(95)02037-J |
0.336 |
|
| 1993 |
Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy Journal of Clinical Psychopharmacology. 13: 41-45. PMID 8486816 DOI: 10.1097/00004714-199302000-00005 |
0.358 |
|
| 1993 |
CHOUINARD G, JONES B, REMINGTON G, BLOOM D, ADDINGTON D, MacEWAN GW, LABELLE A, BEAUCLAIR L, ARNOTT W. A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients Journal of Clinical Psychopharmacology. 13: 25???40. DOI: 10.1097/00004714-199302000-00004 |
0.411 |
|
| 1990 |
Remington G, Menuck M, Schmidt P, Legault S. The remitting atypical psychoses: clinical and nosologic considerations Canadian Journal of Psychiatry. 35: 36. PMID 2317732 DOI: 10.1177/070674379003500106 |
0.388 |
|
| 1989 |
Menuck M, Legault S, Schmidt P, Remington G. The nosologic status of the remitting atypical psychoses Comprehensive Psychiatry. 30: 53-73. PMID 2647402 DOI: 10.1016/0010-440X(89)90118-1 |
0.405 |
|
| 1989 |
Remington G. Pharmacotherapy of schizophrenia Canadian Journal of Psychiatry. 34: 211-220. PMID 2566367 |
0.364 |
|
| Show low-probability matches. |